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GENERAL INTRODUCTION
The general aim of this dissertation is to test the hypothesis that adenosine may
act as a negative feedback regulator for cardiopulmonary chemoreflex (CCR). Powerful
activation of the CCR results in severe hypotension which may lead to brainstem
ischemia and cause release of adenosine into brainstem cardiovascular centers.
Adenosine acting as a central neuromodulator may inhibit the reflex and prevent further
deterioration of cardiovascular homeostasis observed following activation of the CCR.
Adenosine - neuromodulator acting in life or death situations
The role of adenosine as a neuromodulator in the central nervous system has
been well established.

Adenosine operating via A 1 or A2a receptors may inhibit or

activate, respectively, central neurons and the release of neurotransmitters from nerve
terminals.

Generally the inhibitory action of adenosine mediated via A1 receptors

prevails in most of the central nervous system (16; 91). For example, ingestion of
caffeine, a nonselective antagonist of adenosine receptor subtypes, activates central
processes by removing A1 receptor mediated inhibition which prevails over A 2a receptor
mediated facilitation.

However, in the nucleus of the solitary tract (NTS), where

primarily integration of cardiovascular and other autonomic reflexes occur, the
facilitatory A2a adenosine receptors play a dominant role over A 1 receptor mediated
inhibition. This has been shown in classical studies by Barraco and Phillis who found
that selective activation of NTS A2a adenosine receptors and nonselective activation of
adenosine receptor subtypes in via microinjections of adenosine yield similar effects, i.e.
decreases in mean arterial pressure (MAP) and heart rate (HR) (1; 8; 10; 80; 81; 122).
In contrast, selective activation of adenosine A1 receptors located in the NTS evoked
pressor responses, the effect opposite to that evoked by adenosine itself (1; 8; 10; 80;
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81; 122). Adenosine levels in the central nervous system, including the NTS, increase
during critical, life threatening situations such as ischemia, hypoxia, and severe
hemorrhage as well as during stress/hypothalamic defense response (30; 87; 110; 116118; 129; 138; 139).
this

setting

In

adenosine

levels are increased via
two different mechanisms.
Under
(hypoxic)
intracellular

pathological
conditions
ATP

is

catabolized to adenosine
in ischemic neurons and
glial cells and adenosine is

Figure 1. Medullary pathways of the cardiopulmonary and arterial
baroreceptors. Abbreviations: GABA,-amino-butyric acid; GLU, glutamate;
NTS, nucleus of the solitary tract; CVLM, caudal ventrolateral medulla;
IVLM, intermediate ventro lateral medulla RVLM, rostral ventrolateral
medulla; AMB, nucleus ambiguus; IML, intermediolateral column of spinal
cord; SG, sympathetic ganglion; IX, glossopharyngeal nerve; X, vagal nerve.
Modified from Dampney RAL 1994 (32).

released

into

extracellular
Under
conditions,

the
space.

physiological
as

for

example, during hypothalamic defense response ("flight or fight") ATP is neuronally
released into the NTS and immediately catabolized to adenosine in the extracellular
space by ectonucleotidases (118; 142). ATP may be also released from glial cells
stimulated by active central neurons in their proximity and it is rapidly degraded to
adenosine by ectonucleotidases (45; 51).

Therefore, in all these pathological and

physiological situations adenosine acts spatially, as a neuromodulator enveloping
neural circuitry rather than acting as a neurotransmitter at specific synapses.
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Adenosine is released during large homeostatic imbalance between demand and
delivery of oxygen to the central neurons and may act as a neuromodulator correcting
the imbalance.

Crucial reflexes responsible for cardio-respiratory homeostasis are

primarily integrated in the NTS (Figure 1) (32). Therefore, adenosine may play an
important role in regaining homeostasis by modulation of these reflexes at the level of
the NTS. In support of this hypothesis, it has been reported that NTS contains the
greatest density of adenosine uptake sites in the whole central nervous system (14).
The Bezold Jarisch reflex
The Bezold-Jarisch reflex, also known as the cardiopulmonary chemoreflex
(CCR) is one of the homeostatic cardiovascular reflexes integrated in the NTS. This
reflex was initially discovered as a powerful depressor, and cardiac slowing reflex
activated by veratrum alkaloids (3; 18; 34; 62). Further studies showed that this reflex is
evoked by activation of cardiopulmonary chemo-sensitive receptors and mechanosensitive stretch receptors located on sensory vagal C fibers within the left ventricle and
atria in intimate proximity to the coronary vasculature and also within the pulmonary
circulation (5; 18; 27; 50; 68; 85). Chemo-sensitive and mechano-sensitive receptors
are usually supplied by the same vagal afferent fibers and evoke similar reflex
responses (100; 101).

Cardiopulmonary chemo-sensitive receptors are naturally

activated via prostaglandins, radical oxygen species and serotonin released during
cardiac ischemia, infarct and reperfusion (68; 97). For example, serotonin is released
from platelets, aggregating on damaged endothelium (83; 97) and increased serotonin
levels activate 5HT3 serotonin receptors located on vagal cardiopulmonary afferent
fibers (85; 136). Serotonin is also released from endothelial cells of coronary arteries
during hypoxia (17) and catabolism of ATP to ADP may also contribute to this process
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(83). The cardiopulmonary afferents may be also activated via other naturally released
substances, for example, endogenous canabinoids operating via activation of vanilloid
TRPV1 receptors, ATP operating via P2x receptors, nicotine, etc. (44; 67; 93). The
CCR opposes the sympathoactivatory reflexes mediated by bradykinin released in the
ischemic heart (4; 66; 127). This interaction between two opposite reflex effects may
provide fine tuning of cardiovascular regulation during cardiac ischemia as suggested
by Longhurst (66). The CCR pathway is similar to that mediating the arterial baroreflex
and involves glutamatergic activation of NTS neurons, glutamatergic projection from the
NTS to the caudal ventrolateral medulla (CVLM) and GABA-ergic projection from CVLM
to the rostral ventrolateral medulla (RVLM) (132).
Activation of both mechano-sensitive and chemo-sensitive cardiopulmonary
receptors evokes powerful reflex bradycardia, vasodilation and hypotension.

These

reflex responses are cardio-protective as they decrease afterload and heart rate,
reducing oxygen demand in the hypoxic heart, therefore improving left ventricular
function (37; 92; 97). This may help reduce heart muscle damage, prevent pulmonary
edema, and restore cardiovascular balance despite existing coronary hypoperfusion
(37). However, powerful activation of this reflex under ischemic conditions will cause
apnea, exaggerate the decreases in cardiac output and total peripheral resistance
causing profound hypotension thereby decreasing perfusion of vital organs resulting in
cardiogenic shock (34; 48). Several studies showed that this reflex may be responsible
for infarct related bradyarrhythmias, severe hypotension and sudden cardiac death
especially in patients with infarct of the inferior and posterior wall of the heart (23; 68;
135). This reflex may also be responsible for vasovagal syncope, i.e. transient cerebral
ischemia as a result of marked reflex hypotension (68). Sudden cardiac death in young
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athletes is also often attributable to the Bezold-Jarisch reflex (13; 94). Summarizing,
the cardiopulmonary chemoreflex (CCR) may help restore hemodynamic balance during
myocardial ischemia, or it can further exaggerate the imbalance leading to cerebral
ischemia and death. The final outcome may turn positive or negative depending on the
fine tuning of this powerful reflex mechanism within the central nervous system. When
powerful activation of the CCR leads to severe hypotension and brainstem ischemia
adenosine may be released into the NTS and act as a neuromodulator restricting the
reflex and preventing further deterioration of homeostatic imbalance and its deadly
consequences.
Adenosine neuromodulation of cardiovascular control at the level of the NTS
Although adenosine acts spatially during severe hemodynamic imbalance
leading to brainstem ischemia (87; 110; 129; 138; 139) it may create specific patterns of
autonomic responses due to differential location of inhibitory A 1 and facilitatory A2a
receptors on NTS neurons integrating specific cardiovascular reflexes and projecting
finally to specific regional sympathetic outputs (103; 108). Selective stimulation of these
antagonistic receptor subtypes in the NTS results often, but not always, in reciprocal
sympathetic and hemodynamic responses.

Previous studies from our laboratory

showed that selective stimulation of NTS adenosine A 1 receptors evokes mostly (2/3)
pressor responses and differential regional sympathoactivation: preganglionic adrenal
(pre-ASNA) > renal (RSNA)  lumbar (LSNA) sympathetic nerve activity (107). These
responses were mediated via inhibition glutamatergic transmission in the arterial
baroreflex pathway as bilateral sinoaortic denervation + vagotomy as well as blockade
of ionotropic glutamatergic transmission in the NTS abolished the pressor and
sympathoactivatory responses (107). Relatively high variability of pressor/depressor
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and vasoconstrictor/vasodilator responses evoked by stimulation of NTS A 1 adenosine
receptors is a result of simultaneous triggering of 3 vasoactive responses: 1)
sympathetic vasoconstriction; 2) preferential activation of the adrenal medulla, release
of epinephrine into the circulation and -adrenergic vasodilation; 3) release of
vasopressin into the circulation due to inhibition of baroreflex pathway which normally
restricts release of this peptide from hypothalamic nuclei (paraventricular and
supraoptic) (32; 71-73).

Direct assessment of the effect of NTS A1 receptors on

baroreflex control of HR and regional sympathetic outputs confirmed implications from
previous studies that in fact A1 adenosine receptors inhibit arterial baroreflex
mechanisms at the level of the NTS (73; 107). This study showed that stimulation of
NTS A1 adenosine receptors uniformly shifted all baroreflex stimulus response function
curves (for HR, RSNA, pre-ASNA and LSNA) over 50 mmHg toward higher MAP (102).
Following the stimulation greater baroreceptor activation was required to overcome A 1
adenosine receptor-mediated inhibition of neurotransmission in the baroreflex pathway
to evoke baroreflex responses. The baroreflex functions were shifted rightward along
the MAP axis with only minor, regionally specific alterations of the range and gain of
arterial baroreflex control.

This was consistent with inhibition of neurotransmitter

release from baroreceptor afferents terminating in the NTS.
Activation of NTS A2a adenosine receptors, which functionally prevail over A 1
receptors in the NTS, evokes more contrasting regional sympathetic and vascular
responses that those evoked by NTS A1 receptor stimulation.

Following selective

stimulation of A2a adenosine receptors marked decreases in MAP, HR and RSNA are
accompanied with substantial increases in pre-ASNA, whereas no significant changes
in LSNA were observed (104; 105). Note that NTS A2a and A1 receptors reciprocally
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affect MAP and RSNA, have different effects on LSNA; however they both preferentially
activate the adrenal medulla innervated by pre-ASNA. These two receptor subtypes
have also reciprocal effects on regional vasculature: A1 receptors evoke mostly
vasoconstriction (sympathetic and vasopressinergic) (72), whereas A2a receptors elicit
differential regional vasodilation (iliac>>mesenteric>renal) which is mediated mainly by
activation of the adrenal medulla and -adrenergic vasodilation (9; 59). Although NTS
A2a adenosine receptors have highly diverse effects on regional sympathetic outputs
and vascular beds, these receptors do not directly affect baroreflex mechanisms
controlling the sympathetic outputs. The recent study from our laboratory showed that
NTS A2a receptors do not reset regional sympathetic baroreflex function curves along
the MAP axis, therefore they do not alter the reflex reactivity to activation of arterial
baroreceptors by changes in MAP (54). NTS A2a adenosine receptor-mediated
reciprocal shifts in baseline level of regional sympathetic activity (decreases in RSNA
and increases in pre-ASNA) reciprocally altered the range and the gain of baroreflex
control of RSNA (decreases) vs. pre-ASNA (increases). However the baseline shifts
and consequent alterations of range and gain of baroreflex control of these sympathetic
outputs were mediated via non-baroreflex mechanisms as the stimulus-response
baroreflex functions were not shifted along the MAP axis.
Interestingly, adenosine operating in the NTS via A 2a receptors (which
functionally prevail over A1 receptors) was initially considered as a neuromodulator
which facilitates glutamatergic neurotransmission in the arterial baroreflex pathway
because "baroreflex like" global hemodynamic effects (decreases in MAP and HR) were
observed following microinjections into the NTS of adenosine as well as of the selective
agonist of A2a adenosine receptors (CGS 21680) (1; 8; 10; 80; 81; 122). However, more
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precise analysis of regional sympathetic responses evoked by selective stimulation of
NTS A2a adenosine receptors in our laboratory showed that this concept was very
unlikely.

Although MAP, HR and RSNA decreased upon stimulation of NTS A2a

receptors, which was consistent with facilitation of NTS baroreflex mechanisms, LSNA
did not change and pre-ASNA increased in this setting, which was just opposite to
decreases in pre-ASNA response evoked by activation of the arterial baroreflex (99;
104; 105). In addition, bilateral sinoaortic denervation + vagotomy or bilateral inhibition
of glutamatergic transmission in the NTS did not significantly alter the hemodynamic
and regional neural responses to stimulation of NTS A 2a receptors (105; 106). Finally,
the direct assessment of baroreflex stimulus-response function curves confirmed that
NTS A2a adenosine receptors do not reset arterial baroreflex reactivity (54). Taken
together these data indicate that activation of NTS A 2a receptors markedly alters
baseline levels of regional sympathetic nerve activity and blood flow in regional vascular
beds via non-baroreflex mechanisms as these cardiovascular responses are observed
after deafferentation of the NTS. Therefore, it is likely that A 2a receptors may modulate
activity of nerve fibers descending to the NTS from higher structures, most likely from
the hypothalamus which have dense, reciprocal connection with the NTS (32; 64; 96).
A2a receptor-mediated modulation of this descending activity may interact with specific
cardiovascular reflexes integrated in the NTS and finally evoke the diverse regional
cardiovascular and neural responses.
Hypothetical adenosine neuromodulation of the CCR
As it was hypothesized above, adenosine may be released into the NTS during
powerful reflex decreases in MAP evoked by activation of the CCR and inhibit this reflex
preventing potential deadly consequences (fainting or even sudden death).

This
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hypothesis is consistent with inhibitory action of adenosine via A 1 receptors. Since both
the CCR and arterial baroreflex pathways are mediated via the same medullary
structures (NTS, CVLM and RVLM) and neurotransmitters (32; 131) and selective
stimulation of NTS A1 adenosine receptors does inhibit the arterial baroreflex pathway, it
is likely that also the CCR pathway may be inhibited by this adenosine receptor
subtype. However, the potential effect of NTS A2a adenosine receptors, which are much
more functionally relevant in the NTS than their A 1 counterparts, is not so clear.
Although activation of NTS A2a receptors evoked marked, contrasting regional
sympathetic and hemodynamic responses these receptors did not inhibit the arterial
baroreflex pathway at the level of the NTS (54; 104; 105). Interestingly, the pattern of
regional sympathetic responses evoked by selective stimulation of NTS A2a receptors
resemble the pattern occasionally reported following stimulation of the CCR, i.e.
decreases in RSNA, increases in pre-ASNA and no changes in LSNA (40; 52; 130),
although other studies from our laboratory and by others reported uniform CCRmediated inhibition of regional sympathetic outputs (19; 38; 57; 95; 100).

The

similarities between patterns of regional sympathetic responses triggered by the CCR
and stimulation of NTS A2a receptors could suggest that A2a receptors may facilitate the
CCR under some rare circumstances.

This would be against our hypothesis, that

adenosine serves as a negative feedback regulator for the CCR via both A 1 and A2a
receptors located in the NTS. However, our preliminary data showed that both A1 and
A2a receptors may inhibit the regional sympathetic and hemodynamic responses evoked
by stimulation of the CCR (78), which supports our hypothesis that adenosine indeed
inhibits the CCR via both A1 and A2a receptor subtypes which mediate the inhibition via
different mechanisms: A1 receptors may directly inhibit glutamatergic transmission in
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CCR pathway whereas A2a receptors may facilitate release of an inhibitory
neurotransmitter which in turn may inhibit the CCR pathway at the level of the NTS.
Since stimulation of NTS A2a receptors evokes decreases in RSNA, increases in preASNA and no changes in LSNA it was reasonable to speculate that the A 2a receptor
mediated inhibition of the CCR responses will be regionally specific: it may be greater
for pre-ASNA as the effect of A2a receptor stimulation is opposite to that evoked by the
CCR and the smallest for RSNA as both NTS A2a receptors and activation of the CCR
inhibit this sympathetic output. The A2a receptor-mediated inhibition of LSNA responses
to stimulation of the CCR may be at intermediate level between those for pre-ASNA and
RSNA.
Among possible inhibitory mechanisms which can be triggered in the NTS to
inhibit the CCR pathway the most plausible choice is GABA released from intrinsic NTS
GABA-ergic neurons or nerve terminals. Although there are no data which confirm the
presence of GABA-ergic negative feedback in the CCR pathway at the level of the NTS,
this GABA-ergic negative feedback is well documented in arterial baro- and chemoreflex
pathways (55; 56; 65; 74; 119-121; 133; 140; 141). In addition, a recent review article by
Zhang and Mifflin postulates that the negative GABA-ergic feedback is probably present
in all cardiovascular reflexes integrated in the NTS (141).
It still remains undocumented if adenosine A1 and A2a adenosine receptors are
present in the CCR pathway. It is likely that NTS A1 receptors inhibit the CCR pathway
similarly as they inhibit the arterial baroreflex pathway (102). However, the presence of
A2a receptors in the CCR pathways is not so certain as these receptors did not inhibit or
facilitate arterial baroreflex control of the regional sympathetic outputs.
The studies performed in frame of this dissertation answered all the above
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questions and positively proved the main hypothesis that adenosine operating via both
A1 and A2a receptors in the NTS network serves as a negative feedback regulator for
CCR control of regional sympathetic outputs and hemodynamic variables.
Experimental plan
Adenosine differentially modulates arterial baroreflex control of regional
sympathetic outputs via A1 and A2a receptors located in the NTS circuitry. Based on
previous studies and preliminary data I hypothesize that antagonistic A 1 and A2a
adenosine receptors may act in concert although via different mechanisms to inhibit the
CCR. Adenosine is released into the NTS during hypoxia and severe post-hemorrhagic
hypotension; it may be also released during profound reflex hypotension which occurs
during powerful activation of the CCR. Therefore adenosine operating via both A 1 and
A2a receptors may serve as a negative feedback regulator for CCR mechanisms at the
level of the NTS.
In addition, controversies in literature exist on regional sympathetic responses to
activation of the CCR. Therefore, before addressing modulatory effect of adenosine
receptor subtypes on CCR control of regional sympathetic outputs the differential
regional reflex effects will be assessed using simultaneous recordings from three
sympathetic nerves (renal, adrenal and lumbar).
Specific aims of dissertation
1.

To test hypothesis that activation of A1 adenosine receptors in the NTS
differentially inhibits hemodynamic and regional sympathetic responses evoked
by activation of the CCR.

2.

To test hypothesis that activation of NTS A2a receptors (acting in concert with A1
receptors) differentially inhibits the CCR control of regional sympathetic outputs.
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3.

To test hypothesis that activation of NTS A2a adenosine receptors mediates
inhibition of hemodynamic and regional neural sympathetic responses evoked by
activation of the CCR via facilitating of GABA release from NTS GABA-ergic
neurons/terminals.
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CHAPTER 1
Activation of NTS A1 adenosine receptors inhibits regional sympathetic
responses evoked by activation of cardiopulmonary chemoreflex
ABSTRACT
Previously we have shown that, adenosine operating via the A 1 receptor subtype
may inhibit glutamatergic transmission in the baroreflex arc within the NTS and
differentially increase renal (RSNA), preganglionic adrenal (pre-ASNA) and lumbar
(LSNA) sympathetic nerve activity (ASNA>RSNA≥LSNA). Since the cardiopulmonary
chemoreflex and the arterial baroreflex are mediated via similar medullary pathways
and glutamate is a primary transmitter in both pathways, it is likely that adenosine
operating via A1 receptors in the NTS may differentially inhibit regional sympathetic
responses evoked by activation of cardiopulmonary chemoreceptors.

Therefore, in

urethane/chloralose anesthetized rats (n=37) we compared regional sympathoinhibition
evoked by the cardiopulmonary chemoreflex (activated with right atrial injections of
serotonin 5HT3 receptor agonist, phenylbiguanide, PBG,1-8 g/kg) before and after
selective stimulation of NTS A1 adenosine receptors (microinjections of N6-cyclopentyl
adenosine, CPA, 0.033-330 pmol/50 nl). Activation of cardiopulmonary chemoreceptors
evoked differential, dose dependent sympathoinhibition (RSNA>ASNA>LSNA) and
decreases in arterial pressure and heart rate. These differential sympathetic responses
were uniformly attenuated in a dose dependent manner by microinjections of CPA into
the NTS. Volume control (n=11) and blockade of adenosine receptor subtypes in the
NTS via 8-(p-sulfophenyl) theophylline (8-SPT; 1 nmol in 100 nl) (n=9) did not affect the
reflex responses. We conclude that activation of NTS A 1 adenosine receptors uniformly
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inhibits neural and cardiovascular cardiopulmonary chemoreflex responses.

A1,

adenosine receptors have no tonic modulatory effect on this reflex under normal
conditions. However, when adenosine is released into the NTS (i.e. during stress or
severe hypotension/ischemia) it may serve as negative feedback regulator for
depressor and sympathoinhibitory reflexes integrated in the NTS.
INTRODUCTION
Numerous studies have shown that adenosine operates as a central
neuromodulator of cardiovascular control at the level of the NTS (1; 9; 54; 59; 72; 81;
105; 107; 108; 110; 116).

In the central nervous system adenosine serves as an

inhibiting or stimulating neuromodulator operating via A 1 and A2a receptors, respectively
(90). The primary natural source of adenosine is ATP released from nerve terminals
and glial cells which is subsequently catabolized to adenosine by ectonucleotidases (90;
114; 142). Importantly, adenosine is also released into the extracellular space during
life threatening homeostatic imbalances such as hypoxia, ischemia and severe
hemorrhage; in these pathological situations adenosine results from massive catabolism
of intracellular ATP (87; 110; 129; 138; 139).

Inasmuch as, the most basic, life

supporting, reflexes (cardiovascular, respiratory and other autonomic reflexes) are
primarily integrated in the NTS (32), it is not surprising that the greatest density of
adenosine uptake sites in the entire central nervous system is located in the NTS (14).
The Bezold-Jarisch reflex (also termed the cardiopulmonary chemoreflex) was
initially discovered as a powerful depressor and cardiac slowing response to veratridine
alkaloids (62). It is mediated by polymodal receptors located on myelinated and
unmyelinated vagal afferents from the cardiopulmonary region which are activated
physiologically via mechanical and/or chemical stimuli as shown in extensive studies
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performed on dogs and cats by Colleridges, Paintal, Dawes and Thoren (26; 27; 34; 84;
85; 126). In the rat the equivalent fibers are unmyelinated afferents which only exhibit
low or high activation thresholds (124; 125). The majority of cardiac vagal afferents
activated by mechanical stimuli in the rat are also activated by the serotonin 5HT 3
receptor agonist, phenylbiguanide (PBG)(100; 101). The cardiopulmonary chemoreflex
may be naturally activated via serotonin released from aggregated platelets during
coronary clot formation or from ischemic endothelial cells (17; 43; 83) as well as via
other naturally released substances, for example, endogenous canabinoids operating
via activation of vanilloid TRPV1 receptors, ATP operating via P2x receptors, nicotine,
etc. (44; 67; 93). Consistently, the cardiopulmonary chemoreflex is markedly enhanced
during the acute phase of myocardial infarction (67; 93) which may be cardio-protective
as it causes decreases in HR and afterload leading to decreased oxygen demand of the
ischemic heart (37; 68; 97). However, powerful activation of this reflex may lead to
severe hypotension, cerebral ischemia, bradyarrhythmia and even sudden cardiac
death (13; 48; 68).

If the reflex hypotension exceeds the capabilities of brainstem

vascular autoregulation, adenosine may be released into the NTS from ischemic central
neurons and glial cells. This increase in adenosine can have wide ranging, complex
actions on the central integration of cardiovascular reflexes in these settings.
Adenosine operating via A1 receptor subtype in the NTS may inhibit
glutamatergic transmission in the baroreflex arc, reset arterial baroreflex control of heart
rate (HR) and regional sympathetic nerve activity toward higher mean arterial pressure
(MAP) and differentially affect baroreflex functions for renal (RSNA), preganglionic
adrenal (pre-ASNA), postganglionic adrenal (post-ASNA) and lumbar (LSNA)
sympathetic outputs (102; 107). Since the cardiopulmonary chemoreflex and arterial
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baroreflex are mediated via similar medullary pathways and glutamate is a primary
transmitter in both pathways at the level of the NTS (131), it is likely that adenosine
operating via NTS A1 receptors may differentially inhibit regional sympathetic and
hemodynamic responses evoked by activation of cardiopulmonary chemoreceptors.
This mechanism may serve as a negative feedback regulator for the cardiopulmonary
chemoreflex, preventing the potentially deadly effects of over-excitation of the reflex
which could result in life threatening hypotension and bradyarrhythmia. However, it
remains unknown if A1 adenosine receptors are present on those NTS neurons which
mediate the cardiopulmonary chemoreflex. Our previous studies suggested differential
localization of A1 adenosine receptors on NTS neurons targeting different sympathetic
outputs (103; 107). However, it remains unknown if these receptors are differentially
located on those NTS neurons which mediate cardiopulmonary chemoreflex control of
regional sympathetic outputs.

Specifically, it is unknown if activation of NTS A1

adenosine receptors differentially attenuates the inhibition of the pre-ASNA vs. RSNA
vs. LSNA evoked by activation of cardiopulmonary chemoreceptors. The present study
was designed to address the above hypotheses.
In addition, there are controversial reports on the responses of regional
sympathetic outputs evoked by stimulation of cardiopulmonary afferents (19; 38; 40; 52;
57; 95; 100; 101; 130). For example, in some studies stimulation of cardiopulmonary
5HT3 receptors resulted in reflex increases in pre-ASNA, no change in LSNA and
decreases in RSNA (40; 52; 130) whereas other studies showed uniform inhibition of
these regional sympathetic outputs in this setting (19; 38; 95; 100). These discrepancies
may result from comparisons of single nerve recordings performed in different animals
under different experimental conditions in different laboratories. In the present study the
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attempt was made to simultaneously record the reflex responses from all these
sympathetic outputs (renal, adrenal and lumbar) in the same animal to allow quantifying
and comparing the regionally specific differences in the reflex reactivity under identical
experimental conditions.
METHODS
All protocols and surgical procedures employed in this study were reviewed and
approved by the Institutional Animal Care and Use Committee and were performed in
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the
American Physiological Society and published by the National Institutes of Health.
Design
Regional
hemodynamic

sympathetic
(MAP

and

(RSNA,
HR)

pre-ASNA,

responses

post-ASNA

evoked

by

and

graded

LSNA)
stimulation

and
of

cardiopulmonary chemoreceptors via injections into the right atrium of increasing doses
of 5HT3 serotonin receptor agonist, PBG (1, 2, 4, and 8 g/kg) were studied in 57 male
Sprague-Dawley rats (380.0 ± 6.0 g). In 37 rats, A1 adenosine receptors were activated
in the caudal NTS via bilateral microinjections of three different doses of the selective A 1
receptor agonist, N6-cyclopentyl adenosine, (CPA, 0.033, 3.0, and 330 pmol in 50 nl;
numbers of animals in each group were 10, 13, and 14, respectively).

In 9 rats,

adenosine receptors were inhibited with water soluble, nonselective A1 and A2a receptor
antagonist 8-(p-sulfophenyl) theophylline (8-SPT, 1 nmol in 100 nl). In 11 rats, the effect
of bilateral microinjections of vehicle (artificial cerebrospinal fluid, ACF, 50 nl) on
cardiopulmonary chemoreflex reactivity was evaluated.

The cardiopulmonary

chemoreflex stimulus-response curves obtained under control conditions were
compared with the curves obtained approximately 5 min after bilateral stimulation or
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inhibition of NTS A1 adenosine receptors or following volume control. The
cardiopulmonary chemoreflex reactivity was also assessed approximately one hour
after the microinjections of A1 adenosine receptor agonist into the NTS (recovery). The
timeline of the protocols is presented in Figure 2.
CPA 0.033 - 330 pmol/ 50 nl
8- SPT 1 nmol/100 nl
ACF 50nl

CONTROL
PBG (g/kg)

1

2

4

RECOVERY
PBG (g/kg)

EXPERIMENTAL
PBG (g/kg)

8
1

~ 30 min

~ 5 min

2

4

8
1

2

4

8

~ 60 min

Figure 2. Timeline of experiments. Small arrows indicate injections of phenylbiguanide into the right atrium (1-8
g/kg). Double large arrows indicate bilateral microinjections into the NTS of: A1 adenosine receptor agonist CPA
(0.033, 3.3 and 330 pmol in 50 nl), non-selective adenosine receptor antagonist, 8-SPT (1 nmol in 100 nl) or
volume control (microinjections into the NTS of artificial cerebrospinal fluid, ACF, 50 nl).

Instrumentation and measurements
All procedures were described in detail previously (9; 54; 99; 100; 102; 105-107;
109-111). Briefly, male Sprague-Dawley rats (Charles River) were anesthetized with a
mixture of α-chloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized,
connected to a small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially
ventilated with 40% oxygen, 60% nitrogen mixture. Arterial blood gases were tested
occasionally (Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain
Po2, Pco2, and pH within normal ranges. Average values measured at the end of each
experiment were: Po2 = 166.1 ± 5.1 Torr, Pco2 = 35.3 ± 1.4 Torr and pH = 7.43 ± 0.01.
The left femoral artery and vein were catheterized to monitor arterial blood pressure and
infuse drugs and supplementary doses of anesthesia (12–21 mg·kg-1·h-1 of α-chloralose
and 76–133 mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.
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An additional catheter was inserted into the right atrium via right jugular vein for intraatrial PBG injections.
Sinoaortic denervation was performed and tested similarly as it was described in
previous papers from our laboratory (100; 105; 107). This procedure was performed to
minimize baroreflex compensation for the decreases in MAP evoked by stimulation of
cardiopulmonary receptors and also to eliminate possible activation of arterial
chemoreceptors by PBG (15; 58). Importantly, unloading of arterial baroreceptors may
differentially increase the regional sympathetic nerve activity thus it may obscure the
regional differences in cardiopulmonary chemoreflex reactivity (99). Special attention
was paid to preserve the integrity of the vagus nerve during stripping of the bifurcation
of common carotid artery and cutting aortic depressor, superior laryngeal and
sympathetic nerves. Experiments in which stimulation of the cardiopulmonary receptors
with the maximal used dose of PBG (8g/kg) evoked less than 20% decrease in MAP
were not analyzed.
Neural recordings
In each experiment, simultaneous recordings from three (n=26) or two
sympathetic outputs (n=31) were performed. Renal and adrenal nerves were exposed
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed
from midabdominal incision.

Neural recordings were accomplished as described

previously (54; 99; 100; 102; 105-107; 109-111). Neural signals were initially amplified
(2,000–20,000×) with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged
in 1-s intervals. Background noise was determined 30–60 min after the animal was
euthanized, yet still artificially ventilated to leave unaltered any potential movement
artifacts. Determination of noise in pre-ASNA requires long post mortem recording as
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this nerve may be active up to an hour after the euthanasia (21; 22). Resting nerve
activity before each stimulation of the cardiopulmonary receptors was normalized to 100%.
The ratio between preganglionic and total nerve activity was initially tested with
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche) and finally evaluated at the end of each
experiment with hexamethonium (20 mg·kg -1 i.v.).

RSNA was almost completely

postganglionic; 3.8 ± 0.7 % (n = 56) of the activity persisted after the ganglionic
blockade.

LSNA was predominantly postganglionic; 33.1 ± 3.9 % (n = 40) of

preganglionic activity remained after the blockade. According to the criteria established
in our previous studies (54; 99; 102; 105-107; 109-111), pre-ASNA was considered as
predominantly preganglionic if the activity remaining after ganglionic blockade at the
end of each experiment was >75 % or predominantly postganglionic if the remaining
activity after the blockade was <50%. For total of 47 adrenal nerve recordings 37 were
found predominantly preganglionic, 4 predominantly postganglionic, and 6 had
intermediate composition (int-ASNA) where 50-75% of activity remained after the
blockade. Average activity measured after ganglionic blockade was 107.2 ± 3.3 %,
32.7±5.6 % and 65.0±2.2 % for pre-ASNA, post-ASNA and int-ASNA, respectively. PreASNA increased over 100 % likely because of unloading of intact cardiopulmonary and
the remaining peripheral baroreceptors during the decrease in MAP after the ganglionic
blockade. The ganglionic blockade produces usually larger increases in pre-ASNA (1728%) in rats with intact arterial baroreceptors (54; 102; 105). The arterial pressure and
neural signals were digitized and recorded with a Hemodynamic and Neural Data
Analyzer (Biotech Products, Greenwood, IN), averaged over 1-s intervals, and stored on
hard disk for subsequent analysis.
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Microinjections into the NTS
Bilateral microinjections of three different doses of the selective A1 receptor
agonist, CPA (0.033, 3.3 and 330 pmol in 50 nl of ACF) and the nonselective A 1-A2a
receptor antagonist, 8-SPT (1nmol in 100nl of ACF) were made with multibarrel glass
micropipettes into the medial region of the caudal NTS as described previously (9; 54;
102; 105-107; 109-111). The doses and volumes of the agonist and antagonist were
the same as used in our
previous studies (54; 102;
106; 107; 109-111).

The

drugs were dissolved in ACF,
and the pH was adjusted to
7.2 to unify pH across all our
studies; in previous studies
we

used

acidic

A2a

adenosine receptor agonist
Figure 3. Microinjection sites in subpostremal NTS for all CPA
experimental groups. Schematic diagrams show transverse sections of
the medulla oblongata from a rat brain. AP, area postrema; c, central
canal; 10, dorsal motor nucleus of vagus nerve; 12, nucleus of
hypoglossal nerve; Ts, tractus solitarius; Gr, gracile nucleus; Cu,
cuneate nucleus. Scale is shown at bottom; number on left schematic
diagram denotes the rostrocaudal position in millimeters of the section
relative to the obex according to the atlas of the rat subpostremal NTS.
(7). Microinjection sites for different doses of A1 adenosine receptor
6
agonist [N -cyclopentyl adenosine (CPA)], nonselective adenosine
receptor antagonist [8-sulfophenyl theophylline (8-STP)] & volume
control [(microinjections of 50 nl of artificial cerebrospinal fluid (ACF)]
were marked with fluorescent dye. A: ■, 0.033 pmol CPA; ▲, 1 nmol 8SPT; , volume control. B: ●, 3.3 pmol CPA; ○, 330 pmol CPA.

(CGS 21680) which often
precipitated in pH >7.2. In a
separate group of animals
bilateral

microinjections

of

vehicle (50 nl of ACF at pH =
7.2) into the same site of the

NTS were performed as a volume control. All microinjection sites were marked with DiI
lypophilic dye (Molecular Probes, CA) and verified histologically as described previously
(9; 54; 102; 105-107; 109-111). The microinjection sites are presented in Figure 3 using
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diagrams based on the atlas of the rat subpostremal NTS by Barraco et al. (7).
Cardiopulmonary chemoreflex stimulus-response curves
The cardiopulmonary chemoreflex-responses were evoked using intra-atrial
infusions of increasing doses (1-8 g/kg) of the serotonin 5HT3 receptor agonist,
phenylbiguanide (Sigma, 20 g/1ml solution in 0.9% NaCl).
experimentally

well

controlled

method

of

This is a standard,

activation

of

polymodal

chemosensitive/mechanosensitive cardiopulmonary receptors used in most of the
studies in the field (19; 38; 40; 52; 57; 95; 100; 101; 130). To minimize and unify the
effects of receptor adaptation across the experimental conditions, the injections were
always performed in increasing order of doses of PBG with 2.5 min intervals between
the doses, similarly as it was done previously (100; 101). Total time to complete the
stimulus-response curve was ~ 8 min. The stimulus-response curves were obtained
under control conditions, then at least 30 min later, approximately 5 min after bilateral
microinjections of drugs (CPA or 8-SPT) or vehicle into the caudal NTS, and again 60
min after the microinjections of CPA (recovery). Preliminary experiments showed that
two stimulus-response curves obtained under control condition in half an hour interval
revealed similar reactivity of the reflex.

This approach allowed to assess

cardiopulmonary chemoreflex reactivity during the most effective action of NTS
adenosine A1 receptor activation: the maximal hemodynamic and neural responses
evoked by stimulation of A1 adenosine receptors in the NTS with microinjection of CPA
(330 pmol/50 nl) occur approximately 10-20 min after the microinjection (71; 107).
Data analysis
The cardiopulmonary reflex stimulus-response curves for MAP, HR and the
regional sympathetic outputs under control conditions were compared with those
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generated after bilateral stimulation of NTS A1 adenosine receptors, nonselective
blockade of A1 + A2a adenosine receptors, and microinjection of vehicle into the NTS. In
a separate set of analysis control reflex stimulus-response curves obtained before
microinjections of CPA were also compared with those generated ~70 min after the
microinjections (recovery). The maximal reflex responses in all measured variables
were compared between the experimental conditions. The level of inhibition of the
reflex responses exerted by different levels of activation of NTS A 1 receptors (volume
control and three doses of CPA) was calculated according to the equation: (control
response - response after the microinjection into the NTS)/control response x 100%. A
100% inhibition reflected complete abolition of the response.
The analysis of variance and significance of differences between mean values
were calculated using the statistical package SYSTAT version 11 (SYSTAT Software
Inc., Richmond, CA, USA).

Two-way ANOVA for repeated measures was used to

compare the reflex responses of each variable across the experimental conditions
(control vs. microinjection and control vs. recovery) and across four levels of activation
of the cardiopulmonary reflex (four doses of PBG, 1-8g/kg). Two-way ANOVA for
repeated measures was also used to compare simultaneously recorded three nerve
responses (RSNA vs. pre-ASNA vs. LSNA) evoked by four doses of PBG, whereas for
comparison of different nerves and components of the adrenal nerve responses (RSNA
vs. pre-ASNA vs. int-ASNA vs. post-ASNA vs. LSNA) and four doses of PBG a two-way
ANOVA for independent measures was used.

Two-way ANOVA for independent

measures was also used to analyze the reflex responses evoked by volume control
(ACF) and three doses of CPA (0.033-330 pmol) for the three sympathetic outputs
(RSNA vs. LSNA vs. pre-ASNA) at each level of activation of the cardiopulmonary
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chemoreflex. If significant interactions were found (nerve × experimental condition and
nerve × dose), the differences between the means were calculated with a modified
Bonferroni t-test. One-way ANOVA for independent measures followed by modified
Bonferroni t-test was used for comparison of HR and MAP responses evoked by
microinjections of ACF and the three doses of adenosine receptor antagonist, CPA.
The changes in baseline levels of MAP, HR, RSNA, LSNA and pre-ASNA evoked by
bilateral microinjections of three doses of CPA, the adenosine receptor antagonist, and
the respective volume of vehicle were calculated as a difference between baseline
values averaged during the last 30 s preceding the microinjections and the last 30 s of
the 5 min period of the response to microinjections measured before generating the
second cardiopulmonary chemoreflex stimulus response curve. An α-level of P < 0.05
was used to determine statistical significance.
RESULTS
Basal MAP and HR measured before the control cardiopulmonary chemoreflex
stimulus-response curves in each animal (n = 57) were 88.0 ± 1.6 mmHg and 392.7 ±
6.8 beats·min-1, respectively. Approximately 35 min after the control stimulus-response
curves, the basal parameters, measured just before microinjections into the NTS of
selective A1 adenosine receptor agonist (CPA), nonselective A1 + A2a receptors
antagonist (8-SPT) or vehicle (ACF) returned toward normal levels: 89.8 ± 1.7 mmHg
and 383.8 ± 6.3 beats·min-1 for MAP and HR, respectively. Also, in those animals in
which the third stimulus response curve was performed ~60 min after the
microinjections of CPA (recovery, n = 35), basal MAP and HR were similar to those
measured at the beginning of the experiment (85.9 ± 1.5 mmHg and 366.4 ± 8.1
beats·min-1, respectively). There were no substantial differences between these three
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basal levels.

The effects of bilateral microinjections of three doses of selective A1

adenosine receptor agonist (CPA, 0.033, 3.3 and 330 pmol in 50 nl, n=10, 13 and 14,
respectively), nonselective A1 + A2a adenosine receptor antagonist, 8-SPT, 1 nmol in
100 nl, n=9), and vehicle (ACF, 50 nl, n=11) on resting hemodynamic and neural
variables are presented in Table 1. Inasmuch as most of the effects of A1 receptor
Table 1. Changes in baseline values following A1 receptor agonist and nonselective adenosine antagonist. Baseline
values of MAP, HR, RSNA, pre-ASNA and LSNA after bilateral microinjection of the selective NTS A 1 adenosine
receptor agonist (CPA), respective volume control, ACF, and nonselective adenosine receptor antagonist 8-SPT.

Values are means ± SE. *P < 0.05 vs. ACF; #, P<0.05 vs. RSNA; †, P<0.05 vs. LSNA.

activation are mediated via modulation of arterial baroreflex integration (102; 107) which
is abolished by the sino-aortic baroreceptor denervation, the responses to CPA were
limited similarly to what we previously observed after sino-aortic baroreceptor
denervation plus vagotomy, i.e. increases in MAP, RSNA and LSNA were virtually
abolished whereas the increases in pre-ASNA were attenuated (107).

The

hemodynamic and neural responses evoked by bilateral microinjections of adenosine
receptor antagonist (8-SPT) and vehicle (ACF), performed in the present study in
sinoaortic denervated animals, were accentuated compared to the responses observed
in intact animals (54).
Cardiopulmonary chemoreflex differentially inhibits regional sympathetic outputs
An example of original recordings of hemodynamic and neural responses evoked
by increasing activation of cardiopulmonary chemoreflex under control conditions is
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Figure 4. Example of the reflex responses under control
conditions and following adenosine A1 receptor activation.
Cardiopulmonary chemoreflex responses of mean arterial
pressure (MAP), heart rate (HR), renal (RSNA) and
preganglionic adrenal (pre-ASNA) and lumbar (LSNA)
sympathetic nerve activity evoked by increasing doses of
phenylbiguanide into the right atrium under control
conditions (left panels) and following stimulation of NTS A1
adenosine receptors with the highest dose of the selective
agonist, CPA (330 pmol in 50 nl). All recording were
performed in one animal. The blockade of A1 adenosine
receptors in the NTS virtually abolished the reflex
responses.

response curves (Figure 5A) were different across the nerves (PBG dose vs. nerve
interaction, p=0.003).

Interestingly, no differences were observed between the

responses of different components of the adrenal nerve: pre-ASNA, int-ASNA and post
ASNA (PBG dose vs. nerve interaction p=0.913) although the responses of each of the
components were significantly different from the responses in RSNA and LSNA.
Therefore pre-ASNA (n=37) and int-ASNA (n=6) were combined for further calculations
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and considered as a predominantly preganglionic-ASNA (activity remaining after the
ganglionic blockade >50%). Predominantly postganglionic ASNA (n=4) was excluded
from further calculations.
The comparison of control neural
responses recorded in all 57 animals
(Figure 5A, double and triple nerve
recordings
similar

combined)

results

to

yielded

those

very

where

3

sympathetic outputs (RSNA, pre-ASNA
and

LSNA)

were

recorded

simultaneously (Figure 5B, n=21). The
results of two way ANOVA for the triple
nerve

recordings

only

(repeated

measures, nerve factor, p<0.001, PBG
dose vs. nerve interaction p=0.001)
(Figure 5B) were very similar to those
obtained

for

all

combined

neural

recordings (Figure 5A) (nerve factor,
p<0.001,

PBG

dose

vs.

nerve

interaction p=0.003). This attests that
the reflex responses recorded from two
or three sympathetic outputs under the
same experimental conditions were
fully comparable.

Figure 5. Averaged cardiopulmonary chemoreflex
responses to PBG. Hemodynamic and regional neural
responses
evoked
by
gradual
stimulation
of
cardiopulmonary receptors with increasing doses of
phenylbiguanide. A: combined all neural recordings
performed in 57 animals from lumbar
(39)
preganglionic adrenal (37), intermediate adrenal (6)
postganglionic adrenal (4) and renal (56) sympathetic
nerves; number of recordings from each nerve in
parentheses. B: simultaneous neural recordings from
renal, preganglionic adrenal and lumbar sympathetic
nerves performed in 21 animals. MAP, mean arterial
pressure; HR, heart rate; SNA, sympathetic nerve activity.
Data are means ± standard error. Statistical differences,
P<0.05: *, vs. preganglionic adrenal; ‡, vs. intermediate
adrenal †, vs. postganglionic adrenal; #, lumbar vs. renal.
There were no significant differences between the
responses of different components of the adrenal nerve.
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A1 adenosine receptors inhibit cardiopulmonary chemoreflex mechanism at the
level of the NTS
The example of original recordings (Figure 4) shows powerful inhibition of
cardiopulmonary reflex responses following bilateral activation of NTS A 1 adenosine
receptors with the maximal dose of CPA (330 pmol). This effect was dose dependent
as shown in Figure 6. The stimulus response curves were gradually flattened as the
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Figure
6.
Comparisons
of
the
reflex
responses
obtained
under
control
and CPA conditions. Cardiopulmonary reflex responses obtained under control conditions vs. the responses
obtained following volume control (ACF), increasing doses of A1 adenosine receptor agonist (CPA) and adenosine
receptor antagonist (8-SPT)
. Data are means ± standard error. MAP, mean arterial pressure; HR, heart rate;
RSNA, renal, ASNA, preganglionic adrenal, LSNA, lumbar sympathetic nerve activity. *, P<0.05 vs. control.
Increasing activation of A1 adenosine receptors gradually inhibited the reflex responses. Adenosine receptor
antagonist and volume control did not alter the reflex responses.

dose of A1 adenosine receptor agonist (CPA) increased. The smallest dose of the
agonist (CPA, 0.033 pmol) significantly attenuated the reflex control of renal and lumbar
sympathetic outputs and tended to inhibit pre-ASNA reflex responses (control vs.
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experimental conditions effect, p=0.098).

No attenuation of MAP and HR reflex

responses were observed in this setting (control vs. experimental conditions effects,
p=0.469 and p=0.889, respectively). Greater activation of NTS A1 receptors (CPA, 3.3
and 330 pmol) evoked gradual and significant attenuation the reflex responses of all
variables at all levels of activation of the cardiopulmonary chemoreflex. Comparisons
across the nerves (renal, preganglionic adrenal and lumbar) and doses of CPA (from 0,
volume

control,

to

330

pmol)

showed that the nerves responded
differentially to activation of the
reflex (nerve effect, p<0.0001) and
were inhibited by A1 adenosine
receptor

agonist

dependent

in

manner

effect, p<0.0001).

a

dose

(CPA

dose

However, the

inhibition of the reflex responses in
all sympathetic outputs was similar
(no significant nerve vs. CPA dose
interaction).
vehicle

(ACF)

Microinjections
or

of

adenosine

receptor antagonist (8-SPT) did
not affect the reflex responses (far
left and right panels of Figure 6,
respectively).

Figure 7. The inhibition of the control reflex responses evoked by A1
receptor activation. Hemodynamic and regional sympathetic reflex
responses evoked by volume control (ACF) and the increasing
doses of adenosine A1 receptor agonist, CPA microinjected into the
NTS at four different levels of activation of the reflex (intra-atrial
injections of phenylbiguanide, PBG, 1-8 g/kg). Data are means ±
standard error. SNA-sympathetic nerve activity of renal,
preganglionic adrenal and lumbar nerves. CPA exerted significant,
dose dependent inhibition of the reflex responses at all levels of
activation of the reflex, *, P<0.05. No significant differences between
the inhibition of regional sympathetic responses were found.

Figure 7 shows the level of inhibition of the cardiopulmonary chemoreflex after

30
activation of NTS A1 adenosine receptors and respective volume control. Inhibition was
quantified as the % reduction in the control response; therefore 100% inhibition
corresponds to a completely abolished response. The cardiopulmonary chemoreflex
responses of all recorded variables were inhibited in dose dependent manner at each
level of activation of the reflex (highly significant CPA dose effects) (Figure 7).
However, no significant differences in the inhibition of the three regional sympathetic
outputs were found (nerve effects, p>0.05 for all comparisons).

Thus, whereas

Table 2. Averaged cardiopulmonary chemoreflex responses to PBG evoked under control conditions and 1 hour
after microinjection of A1 adenosine receptor agonist CPA

Values are means ± SE. *P<0.05 vs. control.

cardiopulmonary chemoreflex activation elicits markedly differential reductions in
regional sympathetic nerve activity, NTS A1 receptor stimulation inhibits these
responses in a uniform fashion. This inhibition was reversible. Table 2 shows that the
reflex responses completely recovered approximately 60 min after microinjections of the
small and medium doses of CPA into the NTS and tended to recover after the highest
dose (330 pmol) of the agonist (compare Table 2 and Figure 7).
DISCUSSION
The most important finding of the present study is that adenosine operating via
A1 receptors within the NTS powerfully inhibits the cardiopulmonary chemoreflex. In

31
addition, direct comparison of simultaneously recorded renal, adrenal, and lumbar
sympathetic responses showed that activation of cardiopulmonary chemoreceptors
exerts regionally different inhibition of these sympathetic outputs (RSNA>preASNA>LSNA). Despite of the highly significant differences between cardiopulmonary
chemoreflex inhibition of the regional sympathetic outputs, the attenuation of the
cardiopulmonary chemoreflex responses by stimulation of NTS A 1 adenosine receptors
was similar across the sympathetic outputs (RSNA=pre-ASNA=LSNA). Activation of the
CCR evoked the greatest sympathoinhibition in RSNA but smaller in pre-ASNA and the
smallest in LSNA. Stimulation of NTS A1 adenosine receptors inhibited differential CCR
responses in renal, adrenal and lumbar sympathetic outputs to a similar extent.
Potential mechanisms
Adenosine operates in the NTS under both physiological and pathological
conditions.

For example, during the hypothalamic defense response adenosine is

released into the NTS (30) and contributes to the pressor component of this response
via activation of A1 receptors (35; 116; 118). Adenosine is also released into the central
nervous system, including the NTS during ischemia, hypoxia or severe hemorrhage (87;
110; 129; 138; 139). Activation of presynaptic A1 adenosine receptors in the central
nervous system inhibits the release of transmitters from nerve terminals; central
neurons may also be directly inhibited via postsynaptic A 1 adenosine receptors (90). In
the NTS A1 adenosine receptors are present on presynaptic afferent terminals and in
somato-dendritic locations (63).

The present study confirmed our hypothesis that

adenosine operating via A1 receptors may inhibit neurotransmission in cardiopulmonary
chemoreflex pathway at the level of the NTS. These data are consistent with previous
studies from our laboratory which showed that stimulation of NTS A 1 adenosine
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receptors uniformly resets the baroreflex curves for renal, adrenal and lumbar
sympathetic nerve activity toward higher arterial pressure most likely via inhibition of
glutamatergic transmission in this reflex pathway (102; 107). The arterial baroreflex and
cardiopulmonary chemoreflex are mediated via similar neural pathways and glutamate
serves as a primarily neurotransmitter in both reflexes (131). Therefore, the powerful
inhibition of cardiopulmonary chemoreflex responses due to activation of NTS A 1
adenosine receptors was mediated probably via inhibition of glutamate release in this
reflex pathway at the level of the NTS. Interestingly, the attenuation of cardiopulmonary
chemoreflex responses in renal and lumbar sympathetic outputs was already significant
at the lowest level of activation of A1 adenosine receptors (CPA, 0.033 pmol) whereas
hemodynamic and adrenal responses were not yet significantly attenuated at this
concentration of the agonist (Figure 6, second column of graphs). This lower threshold
for adenosine A1 receptor mediated inhibition of renal and lumbar reflex responses may
be a result of differential location/expression of A1 adenosine receptors on NTS neurons
targeting sympathetic outputs directed to different vascular beds and organs.
Stimulation of NTS A1 adenosine receptors differentially increases baseline
sympathetic nerve activity: pre-ASNA>RSNA≥LSNA (107).

The renal and lumbar

sympathoexcitation was abolished via bilateral sinoaortic denervation combined with
vagotomy; the adrenal sympathoexcitation was attenuated in this setting (107).
However, it was unknown if arterial baroreflex afferents or vagal afferents or both
contributed to the sympathoexcitation evoked by stimulation of A1 adenosine receptors
in the NTS. The present study showed that the sinoaortic denervation alone had very
similar effect on baseline shifts of these sympathetic outputs compared to the effect of
combined sinoaortic denervation plus vagotomy [compare Table 1 and ref (107)]. This
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indicates that the sympathoexcitation produced by A1 receptor stimulation, previously
observed in animals with all afferents intact, is mediated via A1 adenosine receptor
inhibition of baroreflex but not cardiopulmonary chemoreflex pathway. Whereas, both
sympathoinhibitory reflexes are powerfully inhibited by activation of NTS A 1 adenosine
receptors the cardiopulmonary chemoreflex has little if any tonic activity thus inhibition
of the arterial baroreflex is most likely responsible for the effects of NTS A 1 adenosine
receptor stimulation in animals with all afferents intact. Collectively, the present and
previous results would support the concept that during stress or the hypothalamic
defense response, adenosine released within the NTS and operating via A 1 receptors
(30; 35; 116; 118) may inhibit sympathoinhibitory reflexes (arterial baroreflex and
cardiopulmonary chemoreflex).
It was not surprising that blockade of adenosine receptors in the NTS did not
affect the cardiopulmonary chemoreflex responses. Adenosine is released into the NTS
mostly in specific physiological or pathological situations (stress, hypoxia, ischemia,
severe hemorrhage) (30; 87; 110; 118; 129; 138; 139).

Therefore under normal

conditions the tonic effects of adenosine are minimal if any. Our previous studies and
reports from other laboratories showed very weak or no effects of blockade of
adenosine receptors under resting, normal conditions. However, the blockade of A 2a or
A1+ A2a receptors in the NTS markedly alters the pattern of autonomic responses to
severe hemorrhage, a pathological condition during which adenosine levels increase in
the central nervous system (110; 129). Summarizing, naturally released adenosine may
have little or no effect on cardiovascular reflexes integrated in the NTS under normal
conditions; however, adenosine neuromodulation may become important during
pathological conditions when ischemia and hypoxia reach the NTS (87; 110; 129; 138;
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139). This is consistent with the hypothesis that adenosine may serve as a negative
feedback regulator for the Bezold Jarisch reflex only under pathological conditions, i.e.
when the reflex causes life threatening hypotension which exceeds compensatory
capability of brainstem autoregulation and adenosine is released into the NTS. It should
be stressed that this reflex is naturally activated and enhanced during cardiac ischemia
(17; 67; 83; 93) and the role of centrally released adenosine in modulation of cardiac
ischemia is unknown .
Differential inhibition of regional sympathetic outputs by cardiopulmonary
chemoreflex
The present study showed that under the same experimental conditions the
Bezold-Jarisch reflex exerts a differential inhibition of regional sympathetic outputs
(RSNA>pre-ASNA>LSNA). This differential pattern of regional sympathoinhibition was
similar to that previously observed with stimulation of arterial baroreceptors under
similar experimental conditions (54; 99; 102). This is consistent with the hypothesis that
similar central pathways mediate both reflexes (131). The renal nerve is functionally
consistent as it facilitates pressor responses via vasoconstriction, increase of sodium
reabsorption and release of renin (39); all these components are inhibited by stimulation
of arterial baroreceptors and perhaps cardiopulmonary chemoreceptors. In the adrenal
nerve ~25% of fibers directed to norepinephrine containing chromaffin cells do not
respond

to

cardiopulmonary

chemoreflex

stimulation

(19).

In

addition

to

vasoconstricting fibers lumbar sympathetic nerve provides vasodilating fibers and also
a substantial number of cutaneous fibers which do not respond strongly to the arterial
baroreflex (33; 49) and likely cardiopulmonary chemoreflex stimuli, as suggested by the
present study. Therefore the differential regional sympathoinhibition observed in the
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present study may be a result of the differential composition of these three nerves.
Interestingly, within the adrenal nerve there were no significant differences between the
different components, although preganglionic and postganglionic outputs to the adrenal
medulla often respond in a reciprocal manner to other stimuli (20; 21; 105). Although
qualitatively similar regional sympathetic responses evoked by stimulation of
cardiopulmonary receptors with PBG were reported previously (19; 38; 95; 100) this is
the first study which allows for quantitative comparisons of the regional sympathetic
responses recorded under identical experimental conditions (simultaneous triple nerve
recordings).
There are only few controversial reports on cardiopulmonary chemoreflex control
of pre-ASNA and LSNA. For example, increases in adrenal nerve activity were reported
in response to intra pericardial infusions of phenylbiguanide (52). It is likely, that the
activation of a subset of epicardiac serotonin 5HT 3 receptors increases pre-ASNA (52);
however, this effect is overwhelmed by activation of all cardiopulmonary chemoreflex
receptors via intra-atrial injections of the agonist. In two other studies typical decreases
in RSNA were accompanied with increases in pre-ASNA and no responses from LSNA
(40; 130). In both these studies intravenous instead intra-atrial infusions of PBG were
performed

and

experiments

urethane/chloralose anesthesia.

were

conducted

under

methohexial

instead

of

Since PBG injected into the femoral vein may be

markedly diluted before reaching the cardiopulmonary area and taking into
consideration that RSNA is inhibited to a much greater extent than LSNA, it is possible
that the stimulation threshold for RSNA inhibition but not LSNA inhibition was reached in
this study (130). It is more difficult to explain the increases in adrenal nerve activity
observed in response to intravenous infusion of PBG (40); perhaps, the infusion of PBG
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into the femoral vein and methohexial anesthesia could be responsible.
A recent study from McAllen's laboratory showed that in contrast to typical
inhibition of RSNA, cardiac sympathetic activity increases in response to stimulation of
cardiopulmonary receptors with PBG, although the reflex cardiac slowing prevail
indicating simultaneous activation of vagal inhibition of the heart (95). Even though
increase in parasympathetic control of the heart may be cardio-protective; simultaneous
increase in sympathetic component increases the probability of cardiac arrhythmia,
especially in the ischemic heart, a condition where the cardiopulmonary chemoreflex is
naturally activated (67; 93).

This potentially cardio-arrhythmic scenario is partially

counteracted by inhibition of the adrenal medulla and decreased humoral activation of
the heart as sympathetic outputs to both epinephrine and norepinephrine releasing
chromafin cells are inhibited by the reflex (19).
Limitations of the method
The method of evoking the cardiopulmonary chemoreflex via intra-atrial infusion
of PBG is widely accepted in the field (19; 38; 40; 52; 57; 95; 100; 101; 130) and allows
for precise experimental control of the levels of activation of the reflex in dose
dependent manner.

It should be stressed that the cardiopulmonary chemoreflex is

mediated via polymodal vagal afferent fibers. For example, the majority of cardiac vagal
afferents responding to mechanical stimulation respond also to PBG (101). Many other
substances may activate the cardiopulmonary chemoreceptors during cardiac ischemia
and the early phase of infarct (for example, ATP via P2x receptors, amadamine via
vanilloid TRPV1 receptors, nicotine, etc) (44; 67; 85; 93). Therefore the serotonin 5HT3
receptor agonist, PBG, may serve as a convenient tool for experimental dissection of
the Bezold Jarisch reflex from other reflexes and humoral mechanisms triggered by
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cardiac ischemia, for example, bradykinin activated sympathoexcitation mediated via
sympathetic afferents from the heart (4; 66).
We used whole nerve adrenal recordings to make feasible simultaneous
recordings from up to 3 sympathetic outputs. Therefore our recordings did not allow us
to distinguish between sympathetic outputs directed to epinephrine vs. norepinephrine
containing chromafin cells. However, this is a minor disadvantage as Cao and Morrison
showed that the cardiopulmonary chemoreflex inhibits both sympathetic outputs; it
inhibits virtually all spinal neurons projecting to the epinephrinergic chromafin cells and
~ ¾ neurons supplying norepinephrinergic chromafin cells (19).
Similarly as in our previous studies we did not use a selective A 1 adenosine
receptor antagonist, as the selective antagonists can be dissolved in dimethyl sulfoxide
(DMSO) but not in water (54; 110).

Microinjections of DMSO into the NTS evoke

profound and long lasting decreases in MAP, HR and all the regional sympathetic nerve
activity (preliminary studies).

Therefore we chose a water soluble, nonselective

antagonist of adenosine receptor subtypes (8-SPT). This antagonist effectively blocked
A1 (and A2a) adenosine receptors in the NTS in a previous study from our laboratory
(110). The blockade of adenosine receptor subtypes, performed in the present study
under normal, physiological conditions, did not have significant effects on responses
evoked by stimulation of the cardiopulmonary chemoreflex in all recorded hemodynamic
and neural variables. Therefore, further quantification of the effect of selective blockade
of A1 adenosine receptors in the NTS was not necessary.
Perspectives
The cardiopulmonary chemoreflex provides regionally specific inhibition of noncardiac sympathetic outputs as well as stimulation of parasympathetic activity to the
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heart (19; 38; 95; 100). This may be cardio-protective by decreasing cardiac afterload
and oxygen consumption but may also lead to a dangerous hypotension and
bradyarrhythmias, fainting and even sudden cardiac death when the cardiopulmonary
chemoreflex (Bezold Jarisch reflex) is highly activated (68). Adenosine operating via A1
receptors in the NTS powerfully inhibits these reflex responses. Since adenosine is
released into the central nervous system during hypotensive phase of severe
hemorrhage (110; 129) it may serve as a negative feedback regulator for the
cardiopulmonary

chemoreflex.

Fine

tuning

of

sympathoinhibitory

and

sympathoexcitatory reflexes originating from vagal cardiopulmonary afferents and
cardiac sympathetic afferents, respectively, has been previously proposed by Longhurst
(66). This parallel tuning of simultaneously activated vagal and sympathetic afferents
(for example, with serotonin released from aggregating platelets during clot formation in
coronary arteries) occurs via reciprocal effects of both reflexes on sympathetic outflow
and arterial pressure as well as via reciprocal inhibition between neuronal pools
mediating both reflexes in the NTS (66). The present study demonstrates that this
parallel tuning mechanism may be supplemented by "the last chance mechanism" of
negative

feedback

mediated

by

adenosine

which

powerfully

inhibits

the

sympathoinhibitory cardiopulmonary chemoreflex preventing life threatening reflex
hypotension. Our previous study showed that another sympathoinhibitory reflex, i.e.
arterial baroreflex, is also inhibited by activation of A 1 (but not A2a) adenosine receptors
in the NTS (54; 102). Taken together, this suggests that adenosine may play a role of
universal negative feedback regulator preventing severe hypotension mediated by
sympathoinhibitory, reflexes primarily integrated in the NTS. Further studies may show
if adenosine inhibits or facilitates sympathoexcitatory reflexes integrated in the NTS (for
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example arterial chemoreflex or sympathetic afferent reflexes).
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CHAPTER 2
Paradoxical inhibition of cardiopulmonary chemoreflex control of regional
sympathetic outputs evoked by activation of NTS A2a adenosine receptors
ABSTRACT
Previously we have shown that stimulation of inhibitory NTS A1 adenosine
receptors attenuates cardiopulmonary chemoreflex (CCR) sympatho-inhibition of renal
(RSNA), preganglionic adrenal (pre-ASNA) and lumbar (LSNA) sympathetic nerve
activity and decreases in arterial pressure and heart rate. We have also shown that
activation of the facilitatory NTS A2a adenosine receptors has differential effects on the
baseline levels of these sympathetic outputs; decreasing RSNA, increasing pre-ASNA
and not changing LSNA. Therefore, we hypothesized that stimulation of A 2a receptors
will facilitate the CCR evoked decreases in RSNA, but it will not change the CCR
responses in LSNA and will attenuate the CCR responses in pre-ASNA. In
urethane/chloralose anesthetized rats (n=38) we compared regional sympathetic
responses evoked by stimulation of the CCR with right atrial injections of the serotonin
5HT3 receptor agonist, phenylbiguanide, (PBG 1-8 g/kg) before and after selective
stimulation or blockade of NTS A2a adenosine receptors (microinjections into the NTS of
CGS-21680 0.2-20 pmol/50 nl or ZM-241385 40 pmol/100 nl, respectively). Surprisingly,
we found that the facilitatory A2a adenosine receptors paradoxically inhibited the
hemodynamic and regional sympathetic reflex responses. The reflex sympathetic
responses were inhibited uniformly despite of the contrasting shifts in baseline
sympathetic activity suggesting that these two effects are mediated via different
mechanisms. Blockade of NTS A2a receptors virtually did not affect the CCR responses
indicating little tonic A2a receptor activity. These data suggest that stimulation of NTS

41
A2a receptors triggers unknown inhibitory mechanism(s) which in turn inhibit
transmission in the CCR pathway at the level of the NTS.
INTRODUCTION
Adenosine operating via A1 and A2a receptors is a powerful central modulator of
cardiovascular reflexes primarily integrated in the nucleus of the solitary tract (NTS) (1;
81; 103; 108; 123). The importance of adenosine neuromodulation occurring in the
NTS is stressed by the fact that the NTS contains the greatest density of adenosine
uptake sites in the entire central nervous system (14). Adenosine is released into the
NTS during life threatening situations.

During the stress/hypothalamic defense

response the source of endogenous adenosine is extracellular ATP released from
descending hypothalamic terminals or activated glial cells and catabolized to adenosine
by ectonucleotidases (30; 116-118; 142).

In contrast, during severe hemodynamic

imbalance (ischemia, hypoxia or severe hemorrhage) intracellular ATP is catabolized to
adenosine inside hypoxic neurons and glial cells and then adenosine is released into
the extracellular space (87; 129; 138; 139).

Despite this global action, adenosine

evokes contrasting effects on regional sympathetic outputs and blood pressure control
via two antagonistic A1 and A2a receptor subtypes which inhibit and activate
neurotransmitter release and central neurons, respectively (90). Our previous studies
showed that selective stimulation of NTS A1 receptors evokes pressor responses and
differential increases in renal (RSNA), preganglionic adrenal (pre-ASNA), and lumbar
(LSNA) sympathetic nerve activity (107) mostly via inhibition of baroreflex restraint of
these sympathetic outputs (102). In contrast, selective stimulation of NTS A2a receptors
evokes depressor responses and greatly diverse regional sympathetic responses:
decreases in RSNA, increases in pre-ASNA, and no changes in LSNA (104; 105).
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These highly contrasting effects of adenosine receptor subtypes on regional
cardiovascular control most likely are the result of differential localization of A 1 and A2a
receptors on NTS interneurons which finally target different sympathetic outputs as we
proposed previously (103; 108).
Our most recent paper showed that stimulation of NTS A 1 adenosine receptors
inhibited the cardiopulmonary chemoreflex (CCR)-mediated regional sympathetic
responses in a uniform way, although this reflex (also known as the Bezold Jarisch
reflex) evoked differential regional sympathoinhibition (RSNA>pre-ASNA>LSNA) (53).
The

Bezold-Jarisch

reflex

is

a

powerful

depressor,

cardiac

slowing

and

sympathoinhibitory reflex activated by polymodal mechano- and chemoreceptors which
transmit information from the cardiopulmonary area to the NTS via unmyelinated vagal
C fibers in the rat (26; 84; 85; 124-126). Powerful activation of this reflex may contribute
to fainting and is even blamed for some episodes of sudden cardiac death in young
athletes (13; 48; 68).
Since A2a adenosine receptors, which dominate in the NTS, usually exert
opposite effects to those evoked by A1 receptors we anticipated that selective activation
of NTS A2a receptors may differentially facilitate the CCR. This was likely because the
same pattern of changes in regional sympathetic outputs that are observed with
stimulation of A2a receptors (104; 105) has also been reported occasionally with
activation of the CCR; e.g., increases in pre-ASNA, decreases in RSNA and no
changes in LSNA (40; 52; 130). However, the majority of previous reports and our most
recent study indicated that CCR differentially inhibits the regional sympathetic nerve
activity (RSNA>ASNA≥LSNA) (19; 38; 53; 95; 100; 131). Therefore, considering the
diverse pattern of regional sympathetic responses to stimulation of NTS A 2a receptors,
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we hypothesized that stimulation of these receptors may facilitate CCR responses to a
greater extent in RSNA than LSNA. In contrast, pre-ASNA reflex responses may be
even attenuated as activation of A2a adenosine receptors and CCR afferents exerts the
opposite effects on this sympathetic output.
We compared the regional sympathetic responses evoked by gradual activation
of CCR afferents before and after stimulation of NTS A 2a adenosine receptors with
increasing doses of the selective agonist (CGS-21680). We also investigated the effect
of inhibition of these receptors with the selective antagonist (ZM-241385) to test
whether A2a receptors are tonically active in the CCR pathway. To our surprise, instead
of differential facilitation of CCR control of regional sympathetic outputs we observed
paradoxical, uniform inhibition of all regional sympathetic reflex responses similar to that
observed previously with stimulation of antagonistic A 1 adenosine receptors in the NTS
(53).
METHODS
All protocols and surgical procedures employed in this study were reviewed and
approved by the Institutional Animal Care and Use Committee and were performed in
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the
American Physiological Society and published by the National Institutes of Health.
Design
We compared

regional

sympathetic (renal, adrenal,

and lumbar)

and

hemodynamic (heart rate, HR, and mean arterial pressure, MAP) responses evoked by
graded stimulation of the cardiopulmonary chemoreceptors before and after selective
activation or inhibition of NTS A2a adenosine receptors in a total of 38 male SpragueDawley rats, weight = 367.4 ± 6.3 g. In 29 rats, the comparisons were made between
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CCR stimulus response function curves obtained under control conditions and
approximately 5 min after microinjections into the NTS of three different doses of the
selective A2a adenosine receptor agonist, CGS-21680, (0.2, 2.0, and 20 pmol in 50 nl;
numbers of animals in each group were 10, 10 and 9, respectively). In an additional 9
rats the CCR function curves were compared before and ~ 5 min after inhibition of NTS
A2a adenosine receptors with a water soluble, selective A 2a receptor antagonist; ZM241385 (40 pmol in 100 nl). The CCR reactivity was also assessed approximately one
hour after the pharmacological manipulations in the NTS (recovery) in 36 rats; in two of
them the evaluation of the recovery reflex curves was impossible for technical reasons.
The timeline of the protocol is presented in Figure 8.

Figure 8. Timeline of CSG-21680 experiments. Small arrows indicate bolus injections of PBG in increasing doses
(1-8 g/kg) into the right atrium in 2.5 min intervals. Double large arrows represent bilateral microinjections into
the NTS of: A2a adenosine receptor agonist CGS-21680 (0.2, 2 and 20 pmol in 50 nl), and selective A2a
adenosine receptor antagonist, ZM-241385 (40 pmol in 100 nl).

Instrumentation and measurements
All procedures were described in detail previously (53; 100; 105-107). Briefly,
male Sprague-Dawley rats (Charles River) were anesthetized with a mixture of αchloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized, connected to a
small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially ventilated with
40% oxygen, 60% nitrogen mixture.

Arterial blood gases were tested occasionally

(Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain Po 2, Pco2, and
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pH within normal ranges. Average values measured at the end of each experiment
were: Po2 = 153.1 ± 8.1 Torr, Pco2 = 33.7 ± 1.2 Torr and pH = 7.4 ± 0.01. The left
femoral artery and vein were catheterized to monitor arterial blood pressure; infuse
drugs and to supplement anesthesia (12–21 mg·kg-1·h-1 of α-chloralose and 76–133
mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.

An

additional catheter was inserted into the right atrium via the right jugular vein for intra
atrial PBG injections. The appropriate position of the catheter in the right atrium was
confirmed post mortem. Sinoaortic denervation was performed and tested similarly as
in the previous studies from our laboratory; special attention was given to preserve the
vagus nerve intact (53; 100; 105; 107).
Neural recordings
In each experiment, simultaneous recordings from three (n=35) or two
sympathetic outputs (n=3) were performed. Renal and adrenal nerves were exposed
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed
from midabdominal incision.

Neural recordings were accomplished as described

previously (53; 100; 105-107). Neural signals were initially amplified (2,000–20,000×)
with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged in 1-s intervals.
Background noise was determined after the animal was euthanized yet artificially
ventilated to leave unaltered any potential movement artifacts.

Resting level of the

nerve activity was normalized to 100% before each stimulation of the cardiopulmonary
receptors.
The ratio between preganglionic and total nerve activity was initially tested with
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche), and finally evaluated at the end of each
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experiment with hexamethonium (20 mg·kg -1 i.v.).

RSNA was almost completely

postganglionic; 9.2 ± 2.6% (n = 38) of the activity persisted after the ganglionic
blockade; LSNA was predominantly postganglionic; 41.4 ± 5.1% (n = 37) of
preganglionic activity remained after the blockade.

Of total of 36 adrenal nerves

recorded 22 were predominantly preganglionic pre-ASNA (>75% of activity remained
after the ganglionic blockade), 4 predominantly postganglionic post-ASNA (<50% of
activity remained after the ganglionic blockade) and 10 had intermediate composition,
int-ASNA (50%-75% of activity remained after the ganglionic blockade). Average levels
of preganglionic, intermediate, and postganglionic adrenal nerve activity after ganglionic
blockade were: 103.8 ± 8.4, 65.4 ± 3.1, 23.3 ± 5.9%, respectively. Similarly as in our
previous study predominantly postganglionic ASNA was excluded from further
calculations whereas pre-ASNA (n=22) and int-ASNA (n=10) were combined as
predominantly preganglionic ASNA (>50% of activity remained after the ganglionic
blockade) (53). Nevertheless, a separate comparison of the effects of adenosine A 2a
receptor agonist and antagonist on all components of the adrenal nerve was also
performed (n=36). The arterial pressure and neural signals were digitized and recorded
with a Hemodynamic and Neural Data Analyzer (Biotech Products, Greenwood, IN),
averaged over 1-s intervals, and stored on the hard disk for subsequent analysis.
Microinjections into the NTS
Bilateral microinjections of three different doses of the selective A 2a receptor
agonist, CGS-21680 (0.2, 2 and 20 pmol in 50 nl of ACF), and the antagonist, ZM241385 (40 pmol in 100 nl of ACF), were made with multibarrel glass micropipettes into
the medial region of the caudal NTS as described previously (9; 53; 105; 107). The
doses and volumes of the agonist and antagonist were the same as used in our
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previous studies (53; 54;
102; 106; 107; 110).

The

drugs were dissolved in ACF
with pH adjusted to 7.2; the
selective

A2a

adenosine

receptor agonist CGS-21680
often precipitates in a pH
>7.2. All microinjection sites
Figure 9. Microinjection sites in the subpostremal NTS for all CGS21680 experimental groups. AP, area postrema; c, central canal; 10,
dorsal motor nucleus of vagus nerve; 12, nucleus of hypoglossal nerve;
Ts, tractus solitarius; Gr, gracile nucleus; Cu, cuneate nucleus. Scale is
shown at the bottom; number on the left of schematic diagram denotes
the rostrocaudal position in millimeters of the section relative to the
obex according to the atlas of the rat subpostremal NTS (7). Bilateral
microinjection sites for different doses of A2a receptor agonist, CGS21680 and A2a receptor antagonist, ZM-241385 were marked with
fluorescent dye. A: , 0.2 pmol CGS-21680; , 2 pmol CGS-21680; B:
, 20 pmol CGS-21680, , 40 pmol ZM-241385.

were

marked

lypophilic
Probes,

with

dye
CA)

histologically

DiI

(Molecular
and

as

verified

described

previously (9; 53; 105; 107).

The microinjection sites are presented in Figure 9 using diagrams based on the atlas of
the rat subpostremal NTS by Barraco et al. (7).
Cardiopulmonary chemoreflex stimulus-response curves
The CCR stimulus-response curves were generated as described in our previous
studies (53; 100; 101). Briefly, the cardiopulmonary receptors were stimulated using
bolus injections into the right atrium of increasing doses (1-8 g/kg) of serotonin 5HT3
receptor agonist, phenylbiguanide (PBG, Sigma, 20 g/1ml solution in 0.9% NaCl) in 2.5
min intervals between the injections.

Total time to complete the stimulus-response

curve was ~ 8 min. The curves were obtained under control conditions; 30 min later,
approximately 5 min after bilateral microinjections of drugs (CGS-21680 or ZM-241385)
into the caudal NTS, and again 60 min after the microinjections, recovery (Figure 8).
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This approach allowed assessment of the CCR reactivity during the most effective
action of the NTS adenosine A2a receptor activation which occurs ~ 5-15 min after the
microinjection of the agonist (105; 106).
Data analysis
The cardiopulmonary reflex stimulus-response curves constructed for MAP, HR
and the regional sympathetic outputs under control conditions were compared with
those generated after bilateral stimulation/inhibition of NTS A 2a adenosine receptors
with microinjections of selective agonist and antagonist, CGS-21680 and ZM-241385,
respectively. Control reflex stimulus-response curves obtained before microinjections of
CGS-21680 or ZM-241385 were also compared with the functions generated ~60 min
after the microinjections (recovery).

The maximal reflex responses in all measured

variables were compared between the experimental conditions. The effects exerted by
different levels of activation of NTS A2a receptors (three doses of CGS-21680, 0.2, 2.0,
and 20 pmol) on the reflex responses were calculated according to the equation:
[(control response - response after the microinjection into the NTS)/control response] x
100%. 100% inhibition reflects complete abolition of the response, whereas negative
values represent facilitation of the reflex responses. The same equation was used to
calculate the effect of inhibition of NTS A2a receptors (ZM-214385) on the reflex
responses.
The data were analyzed using the statistical package SYSTAT version 11
(SYSTAT Software Inc., Richmond, CA, USA).

Two-way ANOVA for repeated

measures was used to compare the reflex responses of each variable across the
experimental conditions (control vs. microinjection and control vs. recovery) and across
four levels of activation of the CCR (four doses of PBG, 1-8 g/kg). Two-way ANOVA
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for independent measures was used to compare control renal (n=38), preganglionic
adrenal (n=32) and lumbar (n=37) sympathetic responses to four doses of PBG. The
effects of three doses of CGS-21680 (0.2-20 pmol) on the reflex responses of the three
sympathetic outputs (RSNA vs. pre-ASNA vs. LSNA) at each level of activation of the
CCR (comparisons of reflex response curves obtained after gradual activation of NTS
A2a adenosine receptors and for changes of the reflex responses vs. control conditions,
%) were also evaluated using two-way ANOVA for independent measures.

If

significant interactions were found (nerve × dose), the differences between the means
were calculated with a modified Bonferroni t-test. One-way ANOVA for independent
measures followed by modified Bonferroni t-test was used for comparison of HR and
MAP reflex response curves obtained after microinjections of the three doses of
adenosine receptor agonist, CGS-21680. The changes in baseline levels of MAP, HR,
RSNA, pre-ASNA and LSNA evoked by bilateral microinjections of CGS-21680 and ZM241385 were calculated as a difference between baseline values averaged during the
last 30 s preceding the microinjections and the last 30 s of the 5 min period of the
response to microinjections measured before generating the second cardiopulmonary
chemoreflex function-curve. An α-level of P< 0.05 was used to determine statistical
significance.
RESULTS
Average resting MAP and HR values measured before the control CCR stimulusresponse curves (n=38) were: 83.5 ± 1.5 mmHg and 411.0 ± 6.1 bpm, respectively.
Basal parameters measured just before NTS microinjections of A2a adenosine receptor
agonist, CGS-21680, or antagonist, ZM-241385, returned to normal resting values: 82.4
± 1.6 mmHg and 405.3 ± 6.3 bpm for MAP and HR, respectively. Also, in those animals
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in which the third reflex curve was generated ~60 min after the microinjections
(recovery, n=36), baseline MAP and HR were similar to those measured at the
beginning of experiment (81.7 ± 1.2 mmHg and 398.2 ± 6.4 bpm, respectively). There
were no differences between these three baseline levels of MAP and HR measured
during three stages of the experiments: control, stimulation or blockade of NTS A 2a
adenosine receptors, and recovery (P>0.05 for all comparisons).
The effect of NTS A2a adenosine receptors on baseline values
The effects of bilateral microinjections of the selective A 2a adenosine receptor
agonist, CGS-21680 (0.2, 2, and 20 pmol in 50 nl, n = 10, 10, and 9, respectively), and
the selective A2a receptor antagonist, ZM-241385 (40 pmol in 100 nl, n = 9) on resting
hemodynamic and neural variables are presented in Table 3. The effects of the smallest
Table 3. Changes in baseline values following A2a receptor agonist and antagonist. Baseline values of MAP, HR,
RSNA, pre-ASNA, and LSNA following bilateral NTS microinjections of selective A2a adenosine receptor agonist,
CGS-21680, and antagonist ZM-241385

Values are means ± SE. P < 0.05 vs. 0.2 pmol CGS; †P<0.05 vs. RSNA; ‡P<0.05 ASNA vs. LSNA; # vs. 0

dose of CGS-21680 (0.2 pmol/ 50 nl) on baseline values were similar to the effects of
bilateral microinjections of 50 nl of ACF (volume control) reported in our previous study
(53). Graded levels of A2a receptor activation (CGS-21680; 2, 20 pmol/ 50 nl) evoked
similar patterns of changes in baseline levels of hemodynamic and regional sympathetic
variables as observed previously: decreases in MAP, HR, RSNA and post-ASNA,
increases in pre-ASNA and much smaller changes in LSNA. (104-106).

Selective

blockade of the A2a adenosine receptors with microinjections of ZM-241385, did not

51
alter baseline levels of any variables (P>0.05).
Activation of NTS A2a adenosine receptors inhibits cardiopulmonary chemoreflex
responses
An
recordings

example
of

of

original

hemodynamic

and

neural responses to activation of the
CCR under control and experimental
conditions is presented in Figure 10
(left and right panels, respectively).
Under

control

activation

of

conditions
the

gradual

cardiopulmonary

receptors by increasing doses of PBG
(1–8 g/kg) evoked dose-dependent
decreases in MAP and HR and
differential

decreases

in

regional

sympathetic nerve activity (RSNA >
pre-ASNA  LSNA) (nerve effect
P<0.0001; nerve vs. dose interaction
P=0.007).

These differential neural

Figure 10. An example of cardiopulmonary chemoreflex
responses in mean arterial pressure (MAP), heart rate (HR),
renal (RSNA), pre-adrenal (pre-ASNA) and lumbar (LSNA)
sympathetic nerve activity evoked by intra-atrial injections of
phenylbiguanide (1-8 g/kg) under control conditions (left
panels) and after stimulation of the NTS A2a adenosine
receptors (right panels) with the highest dose of the A2a agonist,
CGS-21680 (20 pmol in 50 nl). All recordings were performed in
one animal. Stimulation of the A2a receptors in the NTS virtually
abolished the cardiopulmonary chemoreflex responses.

responses were similar to those
observed in our previous study (53). The hemodynamic and neural reflex responses
were powerfully inhibited following bilateral activation of NTS A 2a adenosine receptors
with the maximal dose of CGS-21680 (20 pmol/50 nl) (Figure 10, right panels). This
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effect was dose dependent as shown in Figure 11.

The lowest level of A2a receptor

Figure 11. Comparisons of cardiopulmonary chemoreflex responses obtained under control conditions () vs. the
responses obtained after microinjections of A2a receptor agonist CGS-21680, in increasing doses 0.2, 2 or 20
pmol/ 50 nl or the selective A2a antagonist, ZM-241385, 40 pmol/ 100 nl (). Data are means ± SE. P<0.05 vs.
control;  P<0.05 significant parallel shift of the experimental vs. control curves without significant PBG dose vs.
experimental condition interaction. Progressive activation of A2a adenosine receptors gradually shifted the control
reflex function upward indicating dose dependent inhibition of the reflex responses. The A 2a receptor blockade
had no effect on the reflex responses.

activation (CGS-21680, 0.2 pmol/50 nl) did not alter the control reflex responses (control
vs. experimental condition effect P>0.05 for all variables). Therefore this group may be
considered as a volume control containing a physiologically insignificant amount of the
agonist. Increasing activation of A2a receptors (CGS-21680 2 and 20 pmol) gradually
shifted all neural and hemodynamic reflex response curves upward and flattened them.
At the highest dose of the agonist the inhibitory effect was highly significant (control vs.
experimental condition effect, P<0.0001 for MAP and all the neural outputs and P=0.012
for HR). The slope of all reflex response function curves was significantly alerted vs.
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control conditions (experimental effect vs. PBG dose interactions, P<0.02 for all
variables).
Comparisons across the nerves (renal, pre-adrenal, and lumbar) and doses of
CGS-21680 (0.2-20 pmol/ 50 nl) showed that the nerves responded differentially at
each level of activation of the reflex (nerve effect, P<0.05) and were inhibited in dosedependent manner by A2a receptor agonist (CGS dose effect, P<0.05). However, no
differences were found between the inhibition of the CCR responses in RSNA, vs. preASNA, vs. LSNA; slopes of the curves were similar (no significant nerve x CGS dose
interactions were found).

This suggests that despite the contrasting shifts in the

baseline levels of regional sympathetic nerve activity, the stimulation of NTS A 2a
adenosine receptors similarly inhibited the reflex responses of all sympathetic outputs.
Blockade of A2a adenosine receptors with ZM-241385, did not alter the CCR reactivity of
all variables (far right panels of Figure 11); control vs. blockade condition effect, P>0.05
for all variables.
Interestingly, although stimulation of NTS adenosine A2a receptors reciprocally
affects baseline pre-ASNA vs. post-ASNA there were no differences between the
inhibitions of different components of the adrenal nerve.

Comparisons across pre-

ASNA, int-ASNA and post-ASNA vs. dose of CGS 21680 (0.2-20 pmol) with two-way
ANOVA showed no nerve component effect (P>0.05 at each level of activation of the
reflex).
Figure 12 shows to what extent the reflex responses were inhibited after
activation of NTS A2a adenosine receptors compared to the control reflex responses
(% of inhibition).

A 100% inhibition corresponds to completely abolished CCR

responses. Downward deflections of some bars (which may represent a tendency to
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Figure 12. The inhibition of hemodynamic and regional sympathetic control reflex responses evoked by increasing
doses of the A2a receptor agonist, CGS-21680 (0.2-20 pmol) at four different levels of activation of the reflex
(phenylbiguanide 1-8 g/kg). Data are means ± SE. SNA - renal, preganglionic adrenal and lumbar sympathetic
nerve activity. CGS-21680 exerted significant, dose dependent inhibition of the reflex responses at all levels of
activation of the reflex. No differences between the inhibition of the reflex responses in all regional sympathetic
outputs were found. The negative deflections of the bars may correspond to potential facilitation of the reflex;
however, all the negative bars were not significantly different from zero.

facilitation of the reflex) were not significantly different from zero.

The regional

sympathetic outputs were inhibited by microinjections of the A 2a receptor agonist (CGS21680) in a dose dependent manner (highly significant dose effect P=0.002 for the
lowest level of activation of the CCR and P<0.0001 for all higher levels of the
activation); however, no differences between the inhibition of the sympathetic outputs
were found (nerve effect, P>0.05 for each level of activation of the CCR). Also the
inhibition of all adrenal nerve components (pre-ASNA, int-ASNA and post-ASNA) was
uniform (nerve component effect, P>0.05 for each level of activation of the CCR). MAP
reflex responses were also inhibited in a dose dependent manner (P<0.02) at all but the
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lowest level of activation of the CCR. However, the inhibition of the HR responses was
more variable reaching significance only for the moderate activation of the CCR (4 g of
PBG).
Although the antagonist and the smallest dose of the agonist of A 2a adenosine
receptors had no significant effect on the CCR responses (Figure 11, the far right and
left panels, respectively) the comparison of these two experimental conditions may
suggest that the antagonist may show some tendency to facilitate the reflex at the
moderate level of its activation (Table 4). However, the drug effect reached significance
Table 4. Inhibition of the reflex responses after small dose of A2a agonist and antagonist. Cardiopulmonary
chemoreflex responses, PBG (1-8 g/kg), after microinjections of selective A2a agonist (CGS-21680) or A2a
antagonist (ZM-241385).

Data are expressed as percent inhibition from control responses which are standardized to zero level. Positive
values represent inhibition of the reflex while negative numbers suggest facilitation of the responses. Values are
means ± SE. Two-way ANOVA showed a significant drug effect (P=0.022) at moderate activation of the reflex
(PBG, 2 g/kg) but no differences across the nerves (P>0.05 for all doses of PBG).

only for regional sympathetic responses evoked by moderate activation of the CCR (2g
Table 5. Averaged cardiopulmonary chemoreflex responses to PBG evoked under control conditions and 1 hour after
microinjection of A2a adenosine receptor agonist CGS-21680.

Values are means ± SE. *P<0.05 vs. control
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of PBG) without significant drug vs. nerve interaction.
The A2a-mediated inhibition of the reflex responses was reversible. The CCR
responses almost completely recovered ~60 min following NTS microinjections of A2a
receptor agonists (Table 5).
DISCUSSION
The present study showed that activation of facilitory A2a adenosine receptors in the
NTS paradoxically inhibited CCR hemodynamic and regional sympathetic responses.
The NTS A2a adenosine receptors stimulate neurotransmitter release so it was
surprising that their activation inhibited the CCR.

Although stimulation of NTS A2a

receptors evokes contrasting effects on regional sympathetic outputs (it decreases
RSNA, increases pre-ASNA and does not markedly alter LSNA) the inhibition of the
reflex responses of these sympathetic outputs was similar. This study indicated that
NTS A2a receptors are indeed present on NTS neurons/nerve terminals participating in
CCR neurotransmission and inhibit this neurotransmission similarly as the inhibitory A 1
adenosine receptors did in our previous study (53). Although it seems that NTS A 2a
receptors do not exert a significant, tonic inhibition of the reflex they may be activated
upon release of adenosine into the NTS, for example during hypotensive stage of
severe hemorrhage as we observed it previously (75; 110).
Differential modulation of sympathoinhibitory reflexes by adenosine receptor
subtypes
Selective stimulation of NTS A2a adenosine receptors evokes contrasting
changes in the baseline levels of efferent sympathetic nerve activity: decreases in
RSNA and post-ASNA, increases in pre-ASNA, and no changes in LSNA were
observed (104-106). Therefore, we initially expected that activation of these receptors
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may differentially alter CCR responses of these sympathetic outputs (it could facilitate
RSNA reflex responses, attenuate pre-ASNA responses and less affect LSNA
responses). To our surprise the CCR responses of all these sympathetic outputs were
inhibited similarly.

In addition there were no differences in A 2a receptor mediated

inhibition of different components of the adrenal nerve (pre-ASNA, int-ASNA and postASNA). This indicates that the diverse shifts in baseline levels of regional sympathetic
nerve activity and the inhibition of CCR-evoked responses in these sympathetic outputs
are mediated by two different, most likely independent mechanisms. The inhibition of
the reflex responses was probably mediated via facilitation of inhibitory mechanisms
closely linked to the CCR pathway in the NTS, whereas contrasting shifts of baseline
levels of regional sympathetic activity, mediated via NTS A 2a adenosine receptors, seem
independent of reflex mechanisms and glutamatergic transmission in the NTS. We
showed previously that these baseline shifts persist after sinoaortic denervation
combined with vagotomy as well as after bilateral ionotropic glutamatergic blockade of
the NTS (105; 106). The independent effects on baseline sympathetic activity and the
reflex sympathetic responses were similar to those observed previously where we
assessed the modulatory effects of NTS A2a receptors on arterial baroreflex control of
the regional sympathetic outputs (54). In that study despite the typical contrasting shifts
of baseline levels of pre-ASNA vs. RSNA, no resetting of the stimulus-response
baroreflex functions along MAP axis was observed. We proposed that the shifts of
baseline levels of regional sympathetic nerve activity may be mediated by A 2a
adenosine receptors located on non-glutamatergic projections to the NTS from
hypothalamic nuclei which have dense, reciprocal connections with the NTS (for
example, dorsomedial and paraventricular hypothalamic nuclei) (46; 96; 108).
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Consistent with the uniform inhibition of the CCR responses in regional
sympathetic outputs by NTS A2a adenosine receptors was also a dose dependent
attenuation of MAP responses in this setting. HR responses were also attenuated,
although this effect was accompanied with much greater variability. This variability most
likely arises from counteracting effect of the CCR on parasympathetic and sympathetic
control of the heart. Although the CCR triggers powerful vagal bradycardia, this reflex
also simultaneously activates cardiac sympathetic nerves which oppose the dominating
parasympathetic response, as it has been shown very recently by McAllen's group (25;
31; 95). In addition, NTS A2a adenosine receptors may differentially affect these two
counteracting mechanisms.
Our previous studies showed that NTS A1 adenosine receptors inhibit
glutamatergic transmission in the arterial baroreflex arc and in the CCR, which is
consistent with direct inhibition of glutamate release from nerve terminals or central
neurons by presynaptic and postsynaptic A1 receptors, respectively (53; 102; 107). In
contrast, activation of NTS A2a receptors did not alter arterial baroreflex responses
however it inhibited the CCR responses similarly as A 1 adenosine receptors did;
however, via a different, likely indirect mechanism.
Taken together, the present and previous data show that there are contrasting
functional differences between A1 vs. A2a-adenosine receptors in neuromodulation of
the CCR and arterial baroreflex mechanisms located in the NTS: 1) direct inhibition of
neurotransmission in both reflex pathways is mediated by A 1 receptors, 2) selective,
indirect inhibition of CCR, but not arterial baroreflex, pathway is provided by A 2a
receptors, and 3) contrasting shifts in baseline levels of sympathetic activity mediated
by A2a adenosine receptors are independent of the reflex mechanisms.

These
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functional differences most likely reflect differential localization of adenosine receptor
subtypes on NTS neurons/nerve terminals mediating both sympathoinhibitory reflexes
and targeting different regional sympathetic outputs.

It is worth noticing that the

differences (both functional and neuroanatomical) appear to be greater for A 2a
adenosine receptors, which dominate in the NTS, than for A 1 receptors which exert
uniform, direct inhibition of both reflexes (9; 53; 54; 102; 104-107).
Although stimulation of NTS A2a receptors evoked powerful inhibition of the
hemodynamic and regional sympathetic CCR responses, the blockade of these
receptors exerted only a very small, if any, facilitation of the reflex responses indicating
that A2a receptors do not exert a significant tonic inhibition on this reflex at the level of
the NTS. Lack of marked, tonic adenosine modulation of mechanisms of cardiovascular
control at the level of the NTS and in other medullary cardiovascular centers was
usually observed in our laboratory and by others (53; 54; 110; 123).

This is not

surprising, as adenosine release into the NTS during normal, physiological conditions is
negligible. However, adenosine is released into the central nervous system, including
the NTS, during stress/hypothalamic defense response, severe hemorrhage, ischemia
and hypoxia (30; 87; 110; 116-118; 129; 138; 139). During the severe hemodynamic
imbalance adenosine levels increase several fold in the central nervous system and
then adenosine does modulate neural control of the cardiovascular system (87; 110;
129; 138; 139). In the present study we used relatively small, short lasting activation of
only one subset of receptors participating in the reflex to construct the most specific,
dose dependent hemodynamic and regional neural stimulus-response function curves.
Therefore the CCR depressor responses observed in the present study were too small
and too short lasting by design to expect release of adenosine between CCR
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stimulations.

However, in a preliminary report, we showed that during severe

hemorrhage naturally released adenosine does inhibit neural and hemodynamic CCR
responses and this inhibition is removed by microinjections into the NTS of nonselective
A1/A2a adenosine receptor antagonist, 8-(p-sulfophenyl)theophylline (75).
Potential mechanisms
In contrast to A1 adenosine receptors which exert uniform inhibition of
glutamatergic transmission in both CCR and arterial baroreflex pathways via decrease
in Ca++ influx into the synaptic terminals or postsynaptic hyperpolarization of NTS
neurons (90), the facilitory A2a receptors may exert inhibition of the CCR via more
complex mechanisms.

The paradoxical inhibition of the CCR by A 2a adenosine

receptors may be mediated, for example, via facilitation of GABA release from NTS
GABA-ergic neurons and/or terminals via postsynaptic and/or presynaptic A 2a receptors,
respectively.

A2a receptors may also disinhibit GABA release by removing

dopaminergic inhibition of GABA release via direct A2a-D2 receptor interactions as it was
suggested for basal ganglia (36; 47). Since dopamine itself has been reported to inhibit
afferent activation of NTS neurons (60; 61) it is also possible that A2a receptors may
facilitate this inhibitory mechanism.

A2a receptors may also facilitate a vasoactive

intestinal peptide dependent release of GABA as it has been shown in hippocampal
nerve terminals (29). Since NTS contains glycinergic terminals/receptors, given that
glycine inhibits arterial chemoreflex at the level of the NTS in the rat, and considering
that A2a adenosine receptors may activate glycine release from central neurons, it is
possible that A2a adenosine receptors may inhibit the CCR via facilitation of glycine
release which then would inhibit transmission in this reflex pathway (6; 42; 88). It is also
possible that adenosine A2a receptors facilitate both GABA and glycine release as co-
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localization of glycinergic and GABA-ergic mechanisms in the NTS has been reported
(11); both GABA and glycine mediate CCR responses at the level of the rostral
ventrolateral medulla (131). Which of those potential mechanisms is indeed responsible
for A2a receptor mediated inhibition of the CCR pathway remains to be elucidated in
future studies.
Limitation of the method
Major limitations of the method were described in detail in our previous study
concerning NTS A1 adenosine receptor mediated inhibition of the CCR (53). Briefly, we
believe that this method of evoking the CCR with increasing doses of PBG, which
activate only a subset of CCR afferents, is a good, well controlled experimental tool
widely accepted in the field (19; 38; 40; 52; 57; 95; 100; 101; 130). Selective activation
of serotonin 5HT3 receptors on polymodal vagal afferents from cardiopulmonary area
dissects the activation of CCR from other reflexes and humoral mechanisms which may
be triggered by cardiac ischemia which is known to naturally activate the CCR (17; 50;
67; 83; 93; 97).

Although we could not distinguish between adrenal nerve fibers

supplying adrenergic vs. noradrenergic chromafin cells in the adrenal medulla it has
been shown previously that both these types of adrenal nerve fibers are similarly
inhibited by activation of the CCR (19).
In the present paper we did not provide the microinjection volume control for the
hemodynamic and regional neural responses evoked by the CCR.

However, this

volume control was completed in our previous study and did not show any effects on the
hemodynamic and regional neural reflex responses evoked by activation of the CCR
and the arterial baroreflex (53; 54; 102). In addition, the lowest dose of A2a receptor
agonist (CGS-21680, 0.2 pmol) did not alter the reflex reactivity in all recorded
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variables; therefore it may serve well as a volume control containing physiologically
negligible amount of the agonist.
Perspectives and significance
We reported previously that activation of adenosine A 1 receptors inhibits
glutamatergic transmission in arterial baroreflex and CCR pathways at the level of the
NTS (53; 102; 107). These studies suggested that adenosine, operating via inhibitory
A1 receptors, may attenuate hypotension mediated by sympathoinhibitory reflexes,
which are primarily integrated in the NTS. This mechanism may contribute to fine
tuning of these reflexes in preventing excessive depressor and consequently ischemic
effects. The present study showed that activation of facilitatory A2a receptors in the NTS
paradoxically inhibits CCR control of regional sympathetic outputs although it does not
inhibit baroreflex control of these outputs (54). This indicates that both A1 and A2a
adenosine receptor subtypes act in concert by powerfully inhibiting the CCR; however,
via two different mechanisms: direct and indirect inhibition of neurotransmission in this
reflex arc mediated by A1 and A2a receptors, respectively. The inhibitory effects of NTS
A2a receptors were nearly as powerful as those exerted by NTS A 1 receptors (53). This
shows that adenosinergic inhibition of the CCR at the level of the NTS is much more
potent than the inhibition of baroreflex pathway which is mediated only by NTS A 1
adenosine receptor subtype. This difference may have a physiologic basis because the
cardiopulmonary chemoreflex (or Bezold-Jarisch reflex) may cause more severe
bradycardia and hypotension than that normally evoked by activation of the arterial
baroreflex. Therefore, the CCR needs a stronger negative feedback system compared
to the arterial baroreflex. Powerful activation of the depressor Bezold-Jarisch reflex
may lead to severe hemodynamic imbalance, ischemia and consequently to the release
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of adenosine into the NTS. Then, adenosine may act as especially powerful negative
feedback regulator for this reflex, via both A1 and A2a adenosine receptor subtypes. The
above mechanism may prevent potentially dangerous consequences, for example,
fainting or life threatening bradyarrhythmias, arising from simultaneous activation of
vagal and sympathetic control of the heart, which may lead even to sudden cardiac
death of young athletes (13; 48; 68; 95).
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CHAPTER 3
NTS A2a adenosine receptors inhibit the cardiopulmonary chemoreflex control of
regional sympathetic outputs via GABA-ergic mechanism
ABSTRACT
Adenosine is a powerful central neuromodulator acting via opposite A 1
(inhibitory) and A2a (excitatory) receptors.

However, in the NTS both adenosine

receptor subtypes attenuate cardiopulmonary chemoreflex (CCR) sympatho-inhibition of
renal, adrenal and lumbar sympathetic nerve activity and reflex decreases in arterial
pressure and heart rate. A1 receptors inhibit glutamatergic transmission in the CCR
pathway whereas A2a receptors most likely facilitate release of an unknown inhibitory
neurotransmitter which in turn inhibits the CCR. We hypothesized that A 2a adenosine
receptors inhibit the CCR via facilitation of GABA release in the NTS.

In

urethane/chloralose anesthetized rats (n=51) we compared regional sympathetic
responses evoked by stimulation of the CCR with right atrial injections of serotonin 5HT 3
receptor agonist, phenylbiguanide, (PBG 1-8 g/kg) before and after selective
stimulation of NTS A2a adenosine receptors (microinjections into the NTS of CGS-21680
20 pmol/50 nl) preceded by blockade of GABAA or GABAB receptors in the NTS
(bicuculline 10 pmol /100 nl, or SCH-50911, 1 nmol/100 nl). We found that stimulation
of NTS A2a adenosine receptors inhibits CCR evoked hemodynamic and regional
sympathetic reflex responses via a GABA-ergic mechanism.

Blockade of GABAA

receptors virtually abolished A2a mediated inhibition of the CCR and had tonic effects on
the reflex mechanism.

GABAB receptors had much weaker but significant effects.

These effects were similar for the different sympathetic outputs. We conclude that
adenosine operating in the NTS inhibits CCR integration by both A 1 and A2a receptor
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subtypes, although via very different mechanisms: direct inhibition of glutamate release
and facilitation of GABA release, respectively.
INTRODUCTION
Adenosine modulates cardiovascular reflexes primarily integrated in the nucleus
of the solitary tract via inhibitory A1 receptors and facilitory A2a receptors linked to Gi
and Gs proteins, respectively (1; 16; 81; 90; 103; 108; 115; 123).

Activation of

adenosine A1 and A2a receptors inhibits and facilitates neurotransmitter release and
central neurons via pre- and postsynaptic mechanisms, respectively.

Under

physiological conditions a natural source of adenosine in the NTS is ATP released from
nerve terminals and glial cells and then catabolized by ectonucleotidases; this
mechanism may be triggered by stress/hypothalamic defense response (30; 116-118;
142). Under pathological conditions such as ischemia, hypoxia and severe hemorrhage
intracellular ATP is catabolized to adenosine and adenosine is globally released from
hypoxic neurons and glial cells (87; 129; 138; 138; 139). Therefore adenosine acts
spatially reaching both A1 and A2a receptors in NTS neuronal network. However, this
neuromodulator produces specific patterns of autonomic responses most likely due to
the differential location of these two antagonistic receptors on NTS neurons/terminals
which participate in different reflexes and finally target different sympathetic outputs (98;
103; 104; 107; 108). Selective activation of NTS A1 and A2a receptors usually, but not
always yields reciprocal results. For example, activation of A 2a receptors results in
depressor responses accompanied with contrasting regional sympathetic responses:
decreases in renal (RSNA), increases in preganglionic adrenal (pre-ASNA) and no
changes in lumbar (LSNA) sympathetic nerve activity (98; 104). In contrast, selective
activation of NTS A1 adenosine receptors evokes mostly pressor responses
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accompanied with differential increases in regional sympathetic activity (preASNA>RSNA≥LSNA) (107). Selective stimulation of NTS A1 and A2a receptors has also
different effects on integration of baroreflex control of regional sympathetic outputs: A 1
receptors inhibit glutamatergic transmission which uniformly shifts the baroreflex
stimulus response functions for RSNA, pre-ASNA and LSNA toward higher mean
arterial pressure (MAP) (102; 107); in contrast A2a receptors do not alter the baroreflex
set point although they decrease baseline level of neural activity as well as the gain and
range of the reflex for RSNA and increase all these variables for pre-ASNA via nonbaroreflex mechanisms (54).
These two antagonistic receptors may also act in concert to inhibit the
cardiopulmonary chemoreflex (CCR) control of regional sympathetic outputs acting via
different mechanisms within the NTS. The CCR, also known as Bezold-Jarisch reflex,
is triggered by polymodal mechano- and chemoreceptors and mediated by afferent
vagal C fibers (26; 84; 85; 97; 124-126).

This reflex evokes profound depressor,

cardiac slowing and sympathoinhibitory responses which can lead to fainting and has
been occasionally attributed to sudden cardiac death in young athletes (13; 68; 97).
Inasmuch as activation of A1 receptors inhibits neurotransmitter release, these
receptors likely inhibit the CCR within the NTS by inhibiting glutamatergic transmission
in the CCR pathway similarly as occurs in the arterial baroreflex network (53).

In

contrast, the facilitatory A2a receptors may inhibit the CCR reflex pathway via release of
an inhibitory neurotransmitter (78). The most likely candidate is GABA as stimulation of
central A2a adenosine receptors does facilitate GABA release in different neuronal
networks including respiratory reflexes integrated in the NTS (2; 28; 36; 41; 47; 69; 70;
86; 113; 137). Negative GABA-ergic feedback operating at the level of the NTS in
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arterial baro- and chemoreflex pathways is well documented (55; 56; 65; 74; 119; 120;
128; 133; 140; 141).

There is extensive evidence that both GABAA and GABAB

receptors operate synergistically inhibiting these reflexes at the level of the NTS (55;
120; 128; 140; 141).

Both GABAA and GABAB receptors are tonically active in

modulation of the baroreflex network at the level of the NTS (55; 119; 141).

It is

unknown if GABA-ergic negative feedback also operates in the CCR pathway although
Zhang and Mifflin speculated that GABA may be involved in the regulation of all
cardiovascular reflexes integrated in the NTS (141). Therefore, since activation of A2a
receptors in the NTS inhibits the CCR and these receptors facilitate neurotransmitter
release, we hypothesize that these receptors facilitate GABA release which thereby
inhibits CCR control of regional sympathetic outputs. The present study was designed
to answer the following specific questions: 1) Do NTS A2a adenosine receptors inhibit
the CCR control of regional sympathetic outputs via facilitation of GABA release in the
NTS network? 2) Are both GABAA and GABAB receptors involved? 3) Does GABA
tonically inhibit the CCR pathway under normal conditions?
METHODS
All protocols and surgical procedures employed in this study were reviewed and
approved by the Institutional Animal Care and Use Committee and were performed in
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the
American Physiological Society and published by the National Institutes of Health.
Design
The experiments were performed using 51 male Sprague-Dawley rats, weighing
373.5 g (mean ± SE = 373.5 ± 6.9 g).

In 27 rats the contribution of GABA-ergic

mechanisms to A2a adenosine receptor mediated inhibition of cardiopulmonary
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Figure 13. Timeline of experiments. Small arrows indicate bolus injections of phenylbiguanide (PBG) in increasing
doses (1-8 g/kg) into the right atrium in ~2.5 min intervals. Double large arrows represent bilateral microinjections
into the NTS of: a) artificial cerebrospinal fluid, ACF (100 nl) or GABA A receptor antagonist, Bicuculline (10 pmol/
100 nl) or GABAB receptor antagonist, SCH-5011 (1 nmol/100 nl) followed by A2a adenosine receptor agonist CGS21680 (20 pmol in 50 nl), or b) GABAA receptors antagonist alone (Bicuculline 10 pmol/ 100 nl) or GABAB receptors
antagonist alone (SCH-5011 1 nmol/ 100 nl).

chemoreflex responses of regional neural and hemodynamic variables was assessed;
CCR stimulus response function curves

obtained under control conditions were

compared with the curves obtained after bilateral microinjections into the NTS of A 2a
adenosine receptor agonist (CGS-21680, 20 pmol/50 nl) following pretreatment with:
vehicle control (microinjections of 100 nl artificial cerebrospinal fluid, ACF) or blockade
of NTS GABAA or GABAB receptors (microinjections of Bicuculline, 10 pmol/100 nl, or
SCH-50911, 1 nmol/100 nl, respectively).

To asses potential tonic effects of NTS

GABA-ergic mechanisms on CCR control of regional neural and hemodynamic
variables, in 24 rats the CCR function curves were compared before and after the
GABAA or GABAB receptor blockade alone.

CCR reactivity was also assessed

approximately one hour after the pharmacological manipulation in the NTS (recovery).
The timeline of the protocol is presented in Figure 13.
Instrumentation and measurements
All procedures were described in detail previously (53; 100; 105-107). Briefly,
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male Sprague-Dawley rats (Charles River) were anesthetized with a mixture of αchloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized, connected to a
small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially ventilated with
40% oxygen, 60% nitrogen mixture.

Arterial blood gases were tested occasionally

(Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain Po2, Pco2, and
pH within normal ranges. Average values measured at the end of each experiment
were: Po2 = 156.8 ± 6.2 Torr, Pco2 = 34.3 ± 0.8 Torr and pH = 7.41 ± 0.0. The left
femoral artery and vein were catheterized to monitor arterial blood pressure; infuse
drugs and to supplement anesthesia (12–21 mg·kg-1·h-1 of α-chloralose and 76–133
mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.

An

additional catheter was inserted via the right jugular vein for PBG injections into the right
atrium. The appropriate position of the catheter in the right atrium was confirmed post
mortem. Sinoaortic denervation was performed and tested similarly as in the previous
studies from our laboratory; special attention was given to preserve the vagus nerve
(53; 100; 105; 107).
Neural recording
In each experiment, simultaneous recordings from three (n=41) or two
sympathetic outputs (n=10) were performed. Renal and adrenal nerves were exposed
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed
from midabdominal incision.

Neural recordings were accomplished as described

previously (53; 100; 105-107). Neural signals were initially amplified (2,000–20,000×)
with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged in 1-s intervals.
Background noise was determined after the animal was euthanized yet artificially
ventilated to leave unaltered any potential movement artifacts. Resting level of the
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nerve activity was normalized to 100% before each activation of the CCR.
The ratio between preganglionic and total nerve activity was initially tested with
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche), and finally evaluated at the end of each
experiment with hexamethonium (20 mg·kg -1 i.v.).

RSNA was virtually completely

postganglionic; 7.3 ± 2.4% (n = 48) of the activity persisted after the ganglionic
blockade; LSNA was mostly postganglionic; 34.9 ± 4.3% (n = 51) of preganglionic
activity remained after the blockade. Total of 43 adrenal nerves were recorded with 28
being predominantly preganglionic pre-ASNA (>75% of activity remained after the
ganglionic blockade), 7 were predominantly postganglionic post-ASNA (<50% of activity
remained after the ganglionic blockade) and 8 had intermediate composition, int-ASNA
(50%-75% of activity remained after the ganglionic blockade).

Average levels of

preganglionic, intermediate, and postganglionic adrenal nerve activity after ganglionic
blockade were: 90.2 ± 2.2, 62.4 ± 3.0, 34.7 ± 7.3%, respectively. Stimulation of the
CCR similarly inhibits all three components of the adrenal nerve, although this inhibition
is significantly different than the inhibition of RSNA and LSNA (RSNA>ASNA>LSNA)
(53; 78).

Also activation of A2a adenosine receptors similarly inhibits all three

components of the adrenal nerve (78). Therefore, in the present study all components
of the adrenal nerve were combined for further analysis and referred as ASNA (n=43).
The arterial pressure and neural signals were digitized and recorded with a
Hemodynamic and Neural Data Analyzer (Biotech Products, Greenwood, IN), averaged
over 1-s intervals, and stored on the hard disk for subsequent analysis.
Microinjections into the NTS
Bilateral microinjections of the volume control (ACF, 100 nl), GABA A or GABAB
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receptor blockade (Bicuculline, 10 pmol/ 100 nl or SCH-50911, 1 nmol/ 100 nl,
respectively) followed ~2-3 min later with selective A2a receptor agonist, CGS-21680 (20
pmol in 50 nl of ACF) were made with multibarrel glass micropipettes into the medial
region of the caudal NTS as
described previously (9; 53;
105; 107).

The doses and

volumes of the agonist and
antagonist were the same as
used in previous studies (53;
54; 55; 102; 106; 107; 110;
133).

The

drugs

were

dissolved in ACF with pH
adjusted to 7.2 since the
Figure 14. The microinjection sites for all experiments were located within
subpostremal nucleus tractus solitarii (NTS) as shown in schematic
diagrams of transverse sections of the medulla oblongata from a rat brain.
AP, area postrema; c, central canal; 10, dorsal motor nucleus of vagus
nerve; 12, nucleus of hypoglossal nerve; Ts, tractus solitarius; Gr, gracile
nucleus; Cu, cuneate nucleus. Scale is shown at the bottom; number on
the left of schematic diagram denotes the rostrocaudal position in
millimeters of the section relative to the obex according to the atlas of the
rat subpostremal NTS by Barraco et al. (7). Bilateral microinjection sites
for different pharmacological agents were marked with fluorescent dye. A:
, ACF (100 nl)+CGS-21680(20 pmol/50 nl); , Bicuculline (10 pmol/ 100
nl)+CGS-21680 (20 pmol/50 nl);  SCH-50911 (1 nmol/ 100 nl)+CGS21680 (20 pmol/ 50 nl) B: , Bicuculline (10 pmol/ 100 nl); , SCH
50911 (1 nmol/ 100 nl).

selective

A2a

adenosine

receptor

agonist

CGS-

21680 often precipitates in a
pH >7.2. All microinjection
sites were marked with DiI
lypophilic

dye

(Molecular

Probes, CA) and verified histologically as described previously (9; 53; 105; 107). The
microinjection sites are presented in Figure 14 using diagrams based on the atlas of the
rat subpostremal NTS by Barraco et al. (7).
Cardiopulmonary chemoreflex stimulus-response curves
The cardiopulmonary receptors were stimulated using bolus injections into the
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right atrium of increasing doses (1-8 g/kg) of serotonin 5HT3 receptor agonist,
phenylbiguanide (PBG, Sigma, 20 g/1 ml solution in 0.9% NaCl) in 2.5 min intervals
between the injections (53; 100; 101). Total time to complete the stimulus-response
curve was ~ 8 min. The curves obtained under control conditions were compared with
those obtained 30 min later, approximately 2.5 min after bilateral microinjections of
pharmacological agents into the caudal NTS (either ACF 100 nl or Bicuculline 10
pmol/100 nl or SCH-50911 1 nmol/ 100 nl followed with CGS-21680 20 pmol/50 nl, or
Bicuculline 10 pmol/100 nl or SCH-50911 1 nmol/ 100 nl alone) and again with curves
obtained 60 min after the microinjections, recovery (Figure 13). This approach allowed
assessment of the CCR reactivity during the most effective action of the adenosine A 2a
receptor activation which occurs ~ 5-15 min after the microinjection of the agonist (CGS21680) (105; 106).
Data analysis
The cardiopulmonary reflex stimulus-response curves constructed for MAP, HR,
RSNA, ASNA and LSNA under control conditions were compared with those generated
after bilateral stimulation of NTS A2a adenosine receptors (CGS-21680, 20 pmol/ 50 nl)
preceded by either volume control (ACF, 100 nl) or, GABA A (bicuculline, 10 pmol/ 100
nl) or GABAB (SCH-50911, 1 nmol/ 100 nl) receptors blockade. The CCR function
curves were also compared before and after blockade of either GABA A or GABAB
receptors alone.

Additionally, the control CCR stimulus-response curves were

compared with those generated ~60 min after the microinjections (recovery).

The

maximal reflex responses in all measured variables were compared between the
experimental conditions: ACF+CGS-2160 vs. Bicuculline+CGS-21680 or SCH50911+CGS-21680 and bicuculline alone vs. SCH-50911 alone. The effects exerted by
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activation of A2a receptors preceded by volume control or GABA-ergic blockade on the
reflex responses were calculated according to the equation: [(control response response after the microinjection into the NTS)/control response] x 100%.

100%

inhibition reflects completely abolished CCR response, whereas negative values
represent facilitation of the reflex. The same equation was used to calculate the effects
of blockade of GABAA or GABAB receptors alone on the reflex responses.
The data were analyzed using the statistical package SYSTAT version 11
(SYSTAT Software Inc., Richmond, CA, USA).

Two-way ANOVA for repeated

measures was used to compare the reflex responses of each variable across the
experimental conditions (control vs. microinjection and control vs. recovery) and across
four levels of activation of the CCR (four doses of PBG, 1-8 g/kg). Two-way ANOVA
for independent measures was used to compare control renal (n=48), adrenal (n=43)
and lumbar (n=51) sympathetic CCR responses to four doses of PBG (1-8 g/kg). Twoway ANOVA for independent measures was used to analyze the relative changes in
reactivity for:

ACF+CGS-2160 vs. Bicuculline+CGS-21680 and ACF+CGS-2160 vs.

SCH-50911+CGS-21680. Two-way ANOVA for independent measures was also used
for comparisons of relative changes in the reflex responses of three sympathetic outputs
(RSNA vs. ASNA vs. LSNA) evoked by GABAA vs. GABAB receptor blockades (NTS
microinjections of Bicuculline, 10 pmol/100 nl, vs. SCH-50911, 1 nmol/ 100 nl,
respectively) at each level of activation of the CCR (PBG 1-8 g).

If significant

interactions (nerve × drug) were found, the differences between the means were
calculated with a modified Bonferroni t-test.

One-way ANOVA for independent

measures followed by modified Bonferroni t-test was used for comparison of HR and
MAP reflex response curves. The changes in baseline levels of MAP, HR, RSNA,
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ASNA and LSNA evoked by bilateral microinjections of either ACF or Bicuculline or
SCH-50911 followed by CGS-21680 or effects of microinjections of Bicuculline or SCH50911 alone were calculated as a difference between baseline values averaged during
the last 30 s preceding the microinjections and the last 30 s of the 2.5 min period of the
response to microinjections measured before generating the second cardiopulmonary
chemoreflex function-curve. An α-level of P< 0.05 was used to determine statistical
significance.
RESULTS
Average baseline MAP and HR values measured before the control CCR
stimulus-response curves (n=51) were: 84.8 ± 1.4 mmHg and 398.9 ± 7.2 bpm,
respectively. The baseline values measured just before NTS microinjections of drugs
into the NTS returned to control levels: 82.6 ± 1.5 mmHg and 398.2 ± 4.6 bpm for MAP
and HR, respectively. Also, baseline MAP and HR values measured ~60 min after the
microinjections (recovery, n=51), were not markedly different from those measured at
the beginning of experiment (79.4 ± 1.5 mmHg and 379.1 ± 7.4 bpm, respectively).
Effects of GABA-ergic blockade on NTS A2a adenosine receptor mediated
changes in baseline values
The effects of bilateral microinjections of the selective A 2a adenosine receptor
agonist, CGS-21680 (20 pmol in 50 nl) following volume control (ACF, 100 nl, n=7),
GABAA receptors blockade (Bicuculline, 10 pmol/ 100 nl, n=13), or GABAB receptors
blockade (SCH-50911, 1 nmol/ 100 nl, n=7) on resting hemodynamic and neural
variables are presented in Table 6. Selective activation of A2a adenosine receptors
following volume control evoked a typical pattern of changes in baseline levels of
hemodynamic and regional sympathetic variables as observed in our previous studies
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Table 6. Changes in baseline values under different experimental conditions. Values of MAP, HR, RSNA, ASNA,
and LSNA after bilateral NTS microinjections of selective A2a adenosine receptor agonist CGS-21680, following
respective volume control (ACF), GABAA blockade (Bicuculline) or GABAB receptors blockade (SCH-50911)

Values are means ± SE. *P < 0.05 vs. ACF 100 nl + CGS-21680 (20 pmol/ 50 nl); †P<0.05 vs. RSNA; ‡P<0.05
ASNA vs. LSNA.

during activation of A2a receptors alone: decreases in MAP, HR, and RSNA, increases in
ASNA and much smaller changes in LSNA.

Pretreatment with GABA A receptor

antagonist attenuated A2a receptor mediated decreases in MAP and tended to
decrease changes in all other baseline values; however this effect did not reach
statistical significance.

Pretreatment with GABAB receptor antagonist did not

significantly change A2a receptor-evoked alterations in baseline values although it
tended to reverse the responses in baseline ASNA. Blockade of GABA A and GABAB
receptors alone did not markedly affect the baseline values although it tended to decrease
them slightly (Table 7).
Table 7. Changes in baseline values following GABA-erigc blockade. Values of MAP, HR, RSNA, ASNA, and
LSNA following bilateral NTS microinjections of Bicuculline or SCH-50911 receptors blockade

Values are means ± SE. *P < 0.05 vs. SCH-50911; †P<0.05 vs. RSNA; ‡P<0.05 ASNA vs. LSNA.
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The effects of GABA-ergic blockade on NTS A2a adenosine receptor mediated
inhibition of cardiopulmonary chemoreflex responses
An example of original recordings and the averaged data for hemodynamic and
neural responses evoked by activation of the CCR under control and experimental
conditions are presented in Figures 15 and 16. Under control conditions (Figure 15, left
panels, Figure 16 solid lines) gradual activation of the cardiopulmonary receptors by

Figure 15. An example of cardiopulmonary chemoreflex responses in mean arterial pressure (MAP), heart rate
(HR), renal (RSNA), adrenal (ASNA) and lumbar (LSNA) sympathetic nerve activity evoked by intra-atrial injections
of phenylbiguanide (1-8 g/kg) under control conditions (left panels), and after stimulation of the NTS A2a adenosine
receptors preceded by volume control (CGS-21680 20 pmol/ 50 nl+ACF 100 nl, middle panels) or following
stimulation of the A2a adenosine receptors preceded by GABAA receptor blockade (Bicuculline, 10 pmol/ 100 nl +
CGS-21680, 20 pmol/ 50 nl, in left panels). The left and right panels are recordings preformed in one animal while
the middle panels show powerful inhibition of the CCR responses following activation of A2a receptors recorded in
the other animal (ACF + CGS-21680). GABAA receptor blockade markedly attenuated A2a mediated inhibition of the
CCR responses.
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increasing doses of PBG (1-8 g/kg) evoked dose-dependent decreases in MAP and
HR and uniform, yet differential inhibition in regional sympathetic nerve activity (RSNA >
ASNA > LSNA) similarly as previously observed (53). Two-way ANOVA for all control
data and all levels of the reflex activation showed a significant nerve effect (p < 0.0001)
and nerve vs. dose interaction (p = 0.001). Bilateral activation of NTS A 2a adenosine
receptors following pretreatment with volume control powerfully inhibited the CCR
hemodynamic and neural reflex responses (Figure 15, middle panels, Figure 16 left
panels).

This inhibition was similar to that observed previously when NTS A 2a

adenosine receptors were activated without pretreatment with ACF (78). Blockade of
NTS GABAA receptors abolished the inhibitory effect of adenosine A 2a receptor
stimulation on the CCR (Figure 15, right panels, Figure 16, middle panels). Two-way
ANOVA showed no significant differences between the experimental conditions for all
comparisons; however, slopes for HR and RSNA remained slightly altered after the
blockade (experimental condition vs. dose interactions were significant for these two
variables, P<0.05). The blockade of GABAB receptors decreased NTS A2a receptormediated inhibition of the CCR responses to a lesser extent. The difference between
control and experimental reflex function curves was smaller after GABA B receptor
blockade (Figure 16, right panels) compared to the effect of volume control (Figure 16,
left panels). However, some of A2a receptor mediated inhibition of the reflex responses
persisted after GABAB blockade; two-way ANOVA showed significant experimental
condition effects (P<0.05) for all variables except for HR (Figure 16, right panels).

78

Figure 16. Comparisons of cardiopulmonary chemoreflex responses obtained under control conditions () vs. the
responses obtained after microinjections of either volume control (ACF, 100 nl), GABA A (Bicuculline 10 pmol/ 100 nl),
or GABAB (SCH 50911, 1 nmol/ 100 nl), receptors antagonists followed by A2a receptor agonist (CGS-21680, 20 pmol/
50 nl), (). Data are means ± SE. P<0.05 vs. control;  P<0.05 significant parallel shift of the experimental vs.
control curves without significant PBG dose vs. experimental condition interaction. Activation of A2a receptors
following volume control showed powerful inhibition of the hemodynamic and regional sympathetic CCR responses.
GABAA receptor blockade attenuated adenosine A2a receptor mediated inhibition of the CCR responses, while GABAB
receptors had smaller effect.

Figure 17 shows the extent of A2a mediated-inhibition of the CCR reflex
responses under each experimental condition (pretreatment with volume control vs.
GABAA or GABAB receptor blockade). A 100% inhibition corresponds to a completely
abolished reflex response, while 0% change represents no inhibition of the reflex
reactivity. Selective activation of A2a receptors following volume control (ACF) markedly
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inhibited the CCR responses. This inhibition was virtually abolished by NTS GABA A
blockade; the remaining inhibition was not different from zero for HR and all neural
responses except for RSNA at 4 g of PBG. In contrast, after GABAB receptor blockade

Figure 17. The relative inhibition of hemodynamic and regional sympathetic reflex evoked by stimulation of NTS A 2a
adenosine receptors (CGS-21680, 20 pmol/ 50 nl) after pretreatment with volume control (ACF+CGS), GABA A
receptor blockade (microinjections of Bicuculline, 10 pmol/ 100 nl, BIC+CGS) or GABAB receptor blockade
(microinjections of SCH-50911, 1 nmol/100 nl, SCH+CGS) at four different levels of activation of the reflex
(phenylbiguanide, PBG 1-8 g/kg). Data are means ± SE. SNA - sympathetic nerve activity (renal, adrenal and
lumbar). GABAA receptor blockade removed A2a receptor mediated inhibition of reflex responses to much greater
extent than GABAB receptor blockade.

the inhibition of reflex responses tended to decrease but A 2a receptor activation still
caused significant attenuation of the CCR responses.

Two-way ANOVA showed

significant ACF vs. GABAA blockade effect (P<0.05 for all levels of activation of the
reflex) without significant nerve effects and experimental condition vs. nerve
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interactions. This showed that following GABAA blockade all nerve responses were
similarly restored towards control levels. The GABA B blockade had a much smaller
effect. Two-way ANOVA showed a significant ACF vs. GABAB blockade effect only for
moderate activation of the reflex (PBG 2 and 4 g).
The reflex reactivity returned to normal levels ~ 60 min after GABA receptor
blockade. No significant differences between the experimental conditions were found
for neural and hemodynamic variables (Table 8).
Table 8. Averaged cardiopulmonary chemoreflex responses to PBG (1-8 g/kg) evoked under control conditions
(control) and 1 hour after microinjection of drugs (recovery).

Values are means ± SE. PBG, phenylbiguanide; HR, heart rate, MAP, mean arterial pressure, RSNA, renal
sympathetic nerve activity, ASNA, adrenal sympathetic nerve activity; LSNA, lumbar sympathetic nerve activity.

Figure 18 shows effects of NTS GABA-ergic blockade alone on the CCR
responses. Blockade of GABAA receptors in the NTS tended to exaggerate the reflex
responses (Figure 18, left panels).

However, differences between control and

experimental reflex function curves did not reach statistical significance. Nevertheless,
when more specific comparisons of changes in reflex reactivity were measured at each
level of activation of the reflex they revealed facilitation of the reflex (Figure 19). Figure
19 shows ∆% change of the reflex responses obtained after GABA A and GABAB
blockade compared to the respective control responses. Data were computed similarly
as in Figure 17; upward deflections represent inhibition and downward deflections
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represent facilitation of the reflex responses.

The blockade of GABA A receptors

significantly facilitated CCR reflex responses of all neural and hemodynamic variables
at moderate levels of CCR activation (PBG, 2 and 4 g/kg). In contrast, GABAB
receptor blockade did not alter the reflex reactivity (virtually no significant differences vs.
zero were found). Two-way ANOVA confirmed significant drug effect (Bicuculline vs.
SCH-50911, P<0.05 for all variables at all levels of activation of the reflex). These data
suggest that endogenous GABA operating mostly via GABA A receptors may provide
some tonic inhibition of the CCR pathway at the level of the NTS.

Figure 18. Comparisons of cardiopulmonary chemoreflex
responses obtained under control conditions () vs. the
responses obtained NTS GABAA or GABAB receptor blockades
(microinjections of Bicuculline, 10 pmol/ 100 nl or SCH-50911, 1
nmol/100 nl, respectively) (). Data are means ± SE. GABAA
receptor blockade tended to facilitate the reflex responses
(downward shifts of the reflex function curves obtained after the
blockade).
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Figure 19. The relative changes of hemodynamic and regional sympathetic reflex responses evoked by GABAA
or GABAB receptor blockade in the NTS (microinjections of Bicuculline, 10 pmol/ 100 nl, or SCH-50911, 1
nmol/100 nl, respectively) at four different levels of activation of the cardiopulmonary chemoreflex (intra-atrial
phenylbiguanide, PBG 1-8 g/kg). Data are means ± SE. SNA, sympathetic nerve activity (renal, adrenal and
lumbar). The negative deflections of the bars correspond to facilitation of the reflex in comparison to respective
control conditions. GABAA receptor blockade facilitated the reflex responses; the relative changes in reactivity
were significantly different from zero, especially for moderate activation of the reflex.

DISCUSSION
The present study revealed the mechanism by which A 2a adenosine receptors
exert powerful inhibition of hemodynamic and regional sympathetic CCR responses. In
contrast to A1 adenosine receptors, which directly inhibit glutamatergic transmission in
arterial baro- and cardiopulmonary chemoreflex pathways (53; 102; 107), A2a receptors
facilitate release of GABA which in turn inhibits the CCR network.

Although A 2a

adenosine receptors do not inhibit the arterial baroreflex pathway (54) they provide
powerful GABA-ergic inhibition of the CCR. This GABA-ergic inhibition is mediated
mostly via GABAA receptors with a much smaller contribution of GABAB receptors. The
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inhibition of the reflex responses was similar for different regional sympathetic outputs
despite the marked regional differences in response to stimulation of NTS A2a
adenosine receptors themselves as well as the responses to the CCR. Importantly, the
present study showed for the first time that GABA-ergic feedback operates in the CCR
mechanisms at the level of the NTS and provides slight, although significant, tonic
inhibition of the reflex.
A2a adenosine receptor mediated GABA-ergic inhibition of the CCR
Adenosine A2a receptor–mediated facilitation of GABA release has been shown
in the cerebral cortex, basal ganglia, and hippocampus (2; 28; 36; 41; 47; 69; 70; 86;
113; 137). Further, A2a adenosine receptor mediated facilitation of GABA release in
medullary respiratory centers has been reported as injections of A 2a receptor agonist
CGS-21680 into the fourth ventricle of piglets and rats inhibited respiratory drive and
this effect was abolished by bicuculline (69; 137). Also apnea evoked by stimulation of
the superior laryngeal nerve in piglets was facilitated by A 2a adenosine receptor
stimulation and this inhibition was removed by bicuculline (2). In contrast, selective
stimulation of NTS A2a adenosine receptors does not inhibit arterial baroreflex control of
HR and regional sympathetic outputs (54), although presence of GABA-ergic negative
feedback is well documented in this reflex pathway (55; 56; 65; 74; 119; 120; 128; 133;
140; 141). NTS A2a receptors do modulate baroreflex control of regional sympathetic
outputs; however, only via reciprocal alterations of the baseline levels of renal vs.
adrenal nerve activity which occur via non-baroreflex mechanisms as no resetting of
baroreflex function curves toward higher MAP was observed (54). Although the arterial
baroreflex and the CCR are mediated via similar medullary pathways (131), there was a
significant difference in A2a receptor modulation of these two reflexes, powerful inhibition
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of the CCR observed in the present study and lack of inhibition of arterial baroreflex
reactivity observed in a previous study (54). These differences support the hypothesis
that adenosine receptor subtypes are differentially located in different reflex pathways at
the level of the NTS.
It should be stressed that in the NTS adenosine operates mostly via A 2a
receptors with a much smaller contribution of A1 receptors. This remains in contrast to
action of adenosine in most of the central nervous system where A 1 receptor inhibitory
action prevails (16; 91).

Microinjections of adenosine and selective A2a receptor

agonist, CGS-21680, in to the NTS evoke similar responses, i.e. decreases in MAP
whereas stimulation of NTS A1 adenosine receptors evokes the opposite effect to those
evoked by adenosine and the A2a receptor agonist (8; 10). The less potent A1 receptors
inhibit both arterial baroreflex and CCR mechanisms in the NTS via direct inhibition of
glutamatergic transmission in both pathways. In contrast the dominant A 2a adenosine
receptors selectively inhibit the CCR reactivity via facilitation of GABA release which in
turn inhibits transmission in this reflex arc.
The A2a mediated GABA-ergic inhibition of CCR reactivity was similar across the
regional sympathetic outputs despite both the differential regional sympathetic
responses to CCR activation (RSNA>ASNA>LSNA) (53; 78) as well as the reciprocal
changes in basal levels of regional sympathetic activity evoked by activation of NTS A 2a
adenosine receptors. Therefore, the triggering of GABA-ergic negative feedback by
NTS A2a receptors occurs via mechanisms independent of those responsible for the
contrasting baseline shifts in regional sympathetic activity. The inhibitory mechanisms
seem also independent from those producing differential inhibition of regional
sympathetic outputs by the CCR.
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Contribution of GABAA and GABAB receptors to A2a-mediated inhibition of the
CCR
The present study showed that activation of adenosine A 2a receptors inhibits the
CCR responses mainly via postsynaptic GABAA receptors with a much smaller
contribution of GABAB receptors which are located on both post and presynaptic sites in
the NTS circuitry (55; 119; 140; 141). A2a receptors are located mostly presynaptically
in the NTS (24). Therefore their activation most likely facilitates GABA release from
synaptic terminals. However, it does not exclude the possibility that A2a receptors may
also activate NTS GABA-ergic neurons via a postsynaptic mechanism.

Both these

mechanisms may facilitate the release of GABA which then acts mostly via postsynaptic
GABAA receptors with much lesser effect on the presynaptic action of GABAB receptors.
Both GABAA and GABAB receptors inhibit baroreflex activated neurons in the
NTS (55; 119; 133; 140; 141). Activation of GABAA receptors inhibits responses of NTS
neurons activated from the aortic depressor or vagus nerves to a greater extent than
activation of GABAB receptors (134; 140). The increases in MAP evoked by selective
stimulation of NTS GABAB receptors were reduced ~ 50% following sinoaortic
denervation suggesting presynaptic location of these receptors on arterial baroreflex
afferents (133).

Since the present study was performed on sinoaortic denervated

animals this may partially explain why we observed the predominate role of GABAA
receptors with much smaller contribution of GABAB receptors to A2a adenosine receptor
mediated inhibition of the CCR.
To our knowledge this is the first report demonstrating GABA-ergic inhibition of
the CCR at the level of the NTS. Previous studies confirmed NTS GABA-ergic inhibition
only in arterial baro- and chemoreflex networks (141). The present study showed that
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GABAA but not GABAB receptors exert some tonic inhibitory effect on the CCR. This is
consistent with previous observations that blockade of GABA A receptors increases
spontaneous activity of NTS neurons whereas blockade of GABA B receptors did not
alter activity of these neurons (12; 56; 134).
Other potential inhibitory mechanisms which may be triggered by NTS A 2a
receptors
The present study confirmed our hypothesis that NTS A 2a adenosine receptors
inhibit the CCR reactivity via GABA-ergic mechanism with a dominant role of GABAA
compared to GABAB receptors.

This effect was most likely mediated via direct

facilitation of GABA release from nerve terminals or activation of NTS GABA-ergic
neurons by A2a presynaptic and postsynaptic receptors, respectively. However indirect
facilitation of GABA release by NTS A2a adenosine receptors should be also considered.
For example, activation of A2a receptors may disinhibit GABA release via direct A2a-D2
interactions or via facilitation of release of vasoactive intestinal peptide as it has been
shown in basal ganglia and hippocampal nerve terminals, respectively (29; 36; 47).
A2a adenosine receptors may also facilitate dopamine release and dopamine in
turn may inhibit afferent activation of NTS neurons (60; 61; 112). It is also possible that
A2a receptor mediated facilitation of glycine release may contribute to the inhibition of
the CCR (6; 42; 65). However, this concept is less likely, because glycinergic NTS
neurons were found in the lateral portions of the NTS which are areas not involved in
integration of the CCR (11). In addition, inhibitory potentials triggered in NTS neurons
via afferent vagal stimulation were reduced by blockade of GABA but not glycine (134).
It should be stressed, that A2a receptor-mediated inhibition of the CCR was
virtually abolished by blockade of GABAA receptors and significantly attenuated by
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blockade of GABAB receptors (Figure 16 and 17). These data strongly suggest that the
majority of inhibition of the CCR exerted by A2a adenosine receptors is mediated via
GABA-ergic mechanism with smaller if any contribution of other inhibitory mechanisms
which may be triggered in the NTS by activation of A 2a adenosine receptors.
Nevertheless, all the above potential possibilities should be considered in future studies
addressing mechanisms of inhibitory action of A2a receptors in the NTS.
Limitations of the method
The

limitations

concerning the method of
evoking

the

CCR

responses and whole nerve
recordings were discussed
in detail in our previous
study (53). Here we focus
on

the

limitations

of

blockade of GABA receptor
subtypes

in

Usually

blockade

of

GABAA

receptors

in

nuclei

is

medullary

the

NTS.

Figure 20. An example of effect of bilateral microinjections of high dose of
Bicuculline (100 pmol/100 nl) into the right (R) and left (L) sides of the NTS on
baseline values of mean arterial pressure (MAP), heart rate (HR), adrenal and
lumbar sympathetic nerve activity recorded in one animal. Approximately 10
sec following the microinjections all baselines become markedly unstable.

achieved with up to 500 pmol/ 100 nl of bicuculline (79; 82; 89). However this level of
complete blockade of GABAA receptors in the NTS was not possible as removal of
negative feedback control of all autonomic reflexes integrated in the NTS results in
great instability of hemodynamic and sympathetic variables as

observed

during
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preliminary studies. Figure 20 shows the effect of bilateral microinjection of 100 pmol
of bicuculline in 100 nl of ACF on baseline levels of hemodynamic variables and
regional sympathetic nerve activity.

High amplitude flickering of baseline values

occurred in all variables. Therefore in preliminary studies we assessed the optimal
dose of the antagonist which will effectively inhibit NTS GABA-ergic mechanisms, yet
will not destabilize the resting baseline values so that the reflex responses may be
analyzed and compared with control conditions.

We achieved this effect with

microinjections of 10 pmol of bicuculline in 100 nl volume.

We also attempted to

combine GABAA and GABAB receptors blockade; however, removal of virtually all
GABA-ergic tone in the NTS yielded in marked decreases in baseline levels of MAP, HR
and sympathetic nerve activity which made the comparisons with control conditions very
difficult and perhaps unreliable. Therefore, we abandoned the double blockade.
Perspectives
The present study revealed the presence of GABA-ergic inhibition of the CCR
which may be triggered by stimulation of NTS A 2a adenosine receptors.

NTS A1

adenosine receptors exert similarly powerful inhibition of the CCR (53). Although A1
adenosine receptors inhibit also arterial baroreflex pathway at the level of the NTS, A2a
receptors selectively inhibit the CCR but not arterial baroreflex pathway (54; 102).
Taken together these data show that adenosine operating in the NTS powerfully inhibits
the CCR mechanisms via synergistic action of both antagonistic receptor subtypes
(dominant A2a and secondary A1 receptors) whereas arterial baroreflex is inhibited to
much lesser extent as this occurs only via A1 adenosine receptors. Why then does
adenosine exert such powerful inhibition of the CCR pathway compared to a much
smaller inhibition of the arterial baroreflex pathway?

It is likely that this powerful
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modulation of the CCR via both adenosine receptor subtypes has physiological
implications.

The CCR (also known as the Bezold-Jarisch reflex) evokes life

threatening decreases in MAP via marked sympatho-inhibition, peripheral vasodilation
and severe bradycardia which may result in fainting (13; 68; 97). This reflex is even
implicated in mediating sudden cardiac death in young athletes (13). The powerful
reflex decreases in MAP may lead to brainstem hypoxia and release of adenosine.
Therefore adenosine may work as a negative feedback regulator of this particular
sympathoinhibitory reflex as shown in Figure 21. During cardiac ischemia moderate

Figure 21. Potential fine tuning of the CCR by adenosine released into the NTS. Diagram shows direct and
indirect adenosinergic inhibition of cardiopulmonary chemoreflex (CCR) via A 1 (inhibitory) and A2a (facilitatory)
receptors under conditions when activation of the CCR is becoming detrimental for the organism (BAD) and may
lead to release of adenosine into the NTS. A1 adenosine receptors directly inhibit glutamatergic transmission in the
CCR pathway whereas A2a receptors facilitate the release of GABA which in turn inhibits transmission in the reflex
pathway. Note that moderate activation of the CCR is cardioprotective (GOOD) and does not lead to release of
adenosine into the NTS.

activation of the CCR, buffered by simultaneous activation of sympathetic afferents,
may be helpful as it would reduce afterload and decrease oxygen demand in the
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hypoxic heart.

However, powerful activation of this reflex may be detrimental as

amplification of the hypotension might lead to death. During this severe hypotension
adenosine may be released into the NTS and powerfully inhibit the CCR mechanism via
both receptor subtypes.

This occurs via different mechanisms: direct inhibition of

glutamatergic neurotransmission in the CCR pathway and facilitation of GABA release
via A1 and A2a receptors,
respectively.

This

synergistic inhibitory action
of both adenosine receptor
subtypes may act
strong

negative

regulator

for

as a

feedback
the

CCR

preventing life threatening
effects

of

powerful

activation of this reflex.
This

and

our

previous studies (53; 54;
78; 102) implicate specific,
differential sites of action
for

adenosine

Figure 22. Hypothetical sites of action of A1 and A2a adenosine receptor
subtypes on NTS neurons/terminals mediating the CCR and arterial
baroreflex within NTS network. RVLM and CVLM are rostral and caudal
ventrolateral medulla, respectively.
Dotted arrows represent nerve
terminals descending to the NTS from higher structures via which
adenosine may modulate baseline levels of hemodynamic and neural
variables independently of modulation of the reflex mechanisms. A1
adenosine receptors (filled arrows) may directly inhibit the CCR and arterial
baroreflex pathways while A2a receptors (open arrows) may inhibit the CCR
selectively by activation of GABA-ergic neurons and/or terminals linked to
the CCR pathway in the NTS. Note that the CCR pathway is inhibited by
both adenosine receptor subtypes (A2a receptors which dominate in the
NTS and A1 receptors which are less potent in the NTS) whereas the
arterial baroreflex pathway is inhibited to much lesser extent via the weaker
A1 adenosine receptors only.

receptor

subtypes in sympathoinhibitory cardiovascular reflexes integrated in the NTS (Figure
22). Adenosine operating via the less powerful A1 receptors in the NTS inhibits both the
arterial baroreflex and the CCR via inhibition of glutamate release.

However the

dominant A2a receptors selectively inhibit the CCR via presynaptic facilitation of GABA
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release or postsynaptic activation of NTS GABA-ergic neurons. Specific location of A1
and A2a receptors in NTS circuitry require further investigation. Our preliminary data are
consistent with the implications from our functional studies presented in Figure 22 (76;
77).
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Adenosine is an important neuromodulator of cardiovascular control at the level
of the nucleus of the solitary tract (NTS) where cardiovascular and other autonomic
reflexes are primarily integrated. Levels of adenosine increase in the NTS during life
threatening

hypotension,

ischemia

and

hypoxia.

Adenosine

may

modulate

cardiovascular reflexes to correct hemodynamic imbalance, acting via A 1 and A2a
receptors which inhibit and facilitate neurotransmitter release, respectively. Previous
studies from our laboratory showed that NTS A1 adenosine receptors inhibit the arterial
baroreflex whereas A2a receptors do not reset baroreflex control of regional sympathetic
outputs, although stimulation of these receptors decreases renal (RSNA) increases
preganglionic adrenal (pre-ASNA) and does not alter lumbar (LSNA) sympathetic nerve
activity. Cardiopulmonary chemoreflex (CCR), also known as Bezold-Jarisch reflex,
triggered by various chemicals inhaled or released during myocardial ischemia, may
have beneficial effects when it decreases afterload and heart rate thus decreasing
oxygen demand. However, strong activation of the CCR may cause severe bradycardia
and hypotension leading to hypoperfusion of vital organs, fainting and even death.
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During this severe reflex hypotension adenosine may be released into NTS. Then
adenosine may inhibit the reflex to regain hemodynamic balance.

A 1 adenosine

receptors likely inhibit glutamatergic transmission in the CCR pathway as they inhibit the
arterial baroreflex mediated via similar medullary pathways and transmitters.
Interestingly, preliminary data showed that NTS A2a facilitatory receptors also inhibit the
CCR. Therefore I hypothesized that adenosine operating via both receptor subtypes
may act as negative feedback regulator for CCR control of regional sympathetic outputs
acting via two different mechanisms: A1 receptors mediated direct inhibition and A2a
receptor mediated facilitation of release of an inhibitory neurotransmitter (most likely
GABA) which in turn inhibits the CCR pathway. Since both NTS A1 and A2a adenosine
receptors exert differential effects on regional sympathetic outputs I anticipated that the
inhibition of CCR control of regional sympathetic outputs will be also regionally specific.
In

urethane-chloralose-anesthetized

rats

I

compared

regional

reflex

sympathoinhibition evoked by activation of cardiopulmonary receptors with intra-atrial
injections of phenylbiguanide (1-8 g/kg) before and after stimulation of NTS A1 and A2a
adenosine receptors via microinjections into the NTS of N 6cyclopentyl adenosine (0.33330 pmol/50 nl) and CGS 21680 (0.2-20 pmol/50 nl), respectively. The comparisons
were made also following nonselective blockade of A 1 and A2a receptors ((8-(psulfofenyl) theophyline, 1 nmol/100 nl)) and selective blockade of A 2a receptors (ZM2143285, 40 pmol/ 100 nl) and following respective volume controls.

Gradual

stimulation of both A1 and A2a adenosine receptors located in the NTS caused similar
dose dependent inhibition of hemodynamic and regional sympathetic responses. The
inhibition was independent of differential effects of adenosine receptor subtypes in
regional sympathetic activity suggesting that these two effects are mediated via different
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mechanisms in the NTS. Blockade of adenosine receptor subtypes did not affect the
CCR showing that under normal conditions adenosine levels are too low to affect the
reflex. Blockade of GABAA receptors in the NTS (Bicuculline, 10 pmol/100 nl) removed
A2a receptor mediated inhibition of the reflex whereas blockade of GABA B receptors
(SCH-50911, 1 nmol/100 nl) attenuated the A2a receptor mediated inhibition to a lesser
extent. I found also that GABA operating via GABAA but not GABAB receptors exerts
small, but significant tonic inhibition of the CCR. In addition, simultaneous recordings
from the three sympathetic outputs showed that CCR differentially inhibits regional
sympathetic outputs (RSNA>pre-ASNA>LSNA); this observation clarified inconsistent
reports on CCR control of these sympathetic outputs.
I conclude that adenosine may act as a negative feedback regulator of the CCR
control of neural and hemodynamic variables. NTS A 1 receptors directly inhibit
glutamatergic transmission in the reflex pathway, whereas A 2a receptors facilitate
release of GABA which inhibits the CCR pathway mostly via GABAA receptors.
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